Taking the Stage: Scientific Conferences

Friday, December 9, 2022
New Insights into the Pathogenesis of Thrombotic Thrombocytopenic Purpura: ADAMTS13 Antibody Profiles in TTP
Symposia: Scientific Workshop on Thrombotic Microangiopathies
Program: Scientific Workshops
Time: 2:05 PM-3:10 PM
Location: 293-294 (Ernest N. Morial Convention Center)
Konstantine Halkidis, MD, PhD

A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis
Program: Friday Satellite Symposia
Time: 3:00 PM-6:00 PM
Location: Rhythms Ballroom (Sheraton New Orleans)
Brady L. Stein, MD, MHS and Abdulraheem Yacoub, MD

Saturday, December 10, 2022
151 Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment of CNS Lymphoma, Neurologic Toxicities, and Relapsed/Refractory DLBCL
Symposia: Aggressive Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Time: 12 - 1:30 PM
Location: New Orleans Theater C (Ernest N. Morial Convention Center)
Vivek Patel, MD, Shakthi Bhaskar, MD, Stephen J. Schuster, MD, Loretta J. Nastoupil, MD, Miguel-Angel Perales, MD, Roni Shouval, MD, PhD, Joseph P. McGuirk, DO, Richard T. Maziarz, MD, Andy Chen, MD, PhD, Veronika Bachanova, MD, PhD, David L. Porter, MD, Michael R. Bishop, MD, Peter A. Riedell, MD and Olalekan O. Oluwole, MBBS

236 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients with Suboptimal Response to Ruxolitinib: Final Results from a Phase 2 Study
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis
Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Time: 2:15 PM
Location: 217-219 (Ernest N. Morial Convention Center)
Abdulraheem Yacoub, MD, Uma Borate, MD, Raajit K Rampal, MD, PhD, Haris Ali, MD, Eunice Wang, MD, Aaron T. Gerds, MD, MS, Gabriela S. Hobbs, MD, Marina Kremyanskaya, MD, PhD, Elliott Winton, MD, Casey O’Connell, MD, Swati Goel, MD, Stephen T Oh, MD, PhD, Gary J. Schiller, MD, Albert Assad, MD, Sue Erickson-Viitanen, PhD, Feng Zhou, PhD and Naval Daver, MD

252 Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)
Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Type: Oral
Time: 2:00 PM-3:30 PM
Location: R02-R05 (Ernest N. Morial Convention Center)
Lauren C. Peres, PhD, MPH, Laura B. Oswald, PhD, Christen Dillard, MD, Gabriel De Avila, BS, Taiga Nishihori, MD, Brandon J. Blue, MD, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP, Frederick L. Locke, MD, Melissa Alsina, MD, Omar Alexis Castaneda Puglianini, MD, Leyla O. Shune, MD, Douglas W. Sborov, MD, Charlotte B Wagner, PharmD, Danai Dima, MD, Hamza Hashmi, MD, James Davis, PharmD, M. Hakan Kocoglu, MD, Shebli Atrash, MD, Gary Simmons, DO, Nilesh Kalariya, Christopher J. Ferreri, MD, Aishwarya Sannareddy, MBBS, Aimaz Afrough, MD, Peter M. Voorhees, MD, Jack Khouri, MD, Joseph P. McGuirk, DO, Surbhi Sidana, MD, Doris K. Hansen, MD and Krina Patel, MD, MSc

265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses
Symposia: Allogeneic Transplantation: Disease Response and Comparative Treatment Studies 
Program: Oral and Poster Abstracts
Type: Oral
Time: 2:00 PM-3:30 PM
Location: 391 - 392 (Ernest N. Morial Convention Center)
Caspian Oliai, MD, MS, Rasmus T Hoeg, MD, Anna Pavlova, MD, PhD, Arpita Gandhi, MD, Lori Muffly, MD, Rohtesh S. Mehta, MD, Samer A Srour, MD, MS, Edmund K. Waller, MD, PhD, Robert Lowsky, MD, Sagar S. Patel, MD, Bhagirathbhai Dholaria, MBBS, Carlos Bachier, MD, Jeremy M. Pantin, MD, FACP, Amandeep Salhotra, MD, Joseph P. McGuirk, DO, Nathaniel B Fernhoff, PhD, J Scott McClellan, MD, PhD, Mehrdad Abedi, MD, Robert S. Negrin, MD and Everett H Meyer, MD, PhD

362 Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT
Symposia:  Cellular Immunotherapies: Early Phase and Investigational Therapies Program: Oral and Poster Abstracts
Type: Oral
Time: 4:00 PM-5:30 PM
Location: Great Hall AD (Ernest N. Morial Convention Center)
Sanjeet S Dadwal, MD, Jo-Anne H. Young, MD, Michael W. Schuster, MD, Jean A. Yared, MD, Gary Douglas Myers, MD, Michelle Matzko, MD, PhD, Sama Adnan, PhD, Joshua A. Hill, MD and Rajat Bansal, MD

347 Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter’s Transformation
Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological  Program: Oral and Poster Abstracts
Type: Oral
Time: 4:00 PM-5:30 PM
Location: R06-R09 (Ernest N. Morial Convention Center)
William G. Wierda, MD, PhD, David John Lewis, MBChB, PhD, Paolo Ghia, MD, PhD, Nirav N. Shah, MD, Catherine C. Coombs, MD, Chan Yoon Y. Cheah, MD, Nicole Lamanna, MD, Joanna M. Rhodes, MD, MSCE, Marc Hoffmann, MD, Shuo Ma, MD, Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Talha Munir, MBBS, MRCP, FRCPath, PhD, Manish R. Patel, MD, Alvaro J. Alencar, MD, Constantine S. Tam, MD, MBBS, John F. Seymour, MBBS, PhD, FRACP, Wojciech Jurczak, Ewa Lech-Marańda, MD, PhD, Lindsey E. Roeker, MD, Philip A. Thompson, MBBS, Paolo B. Abada, MD, PhD, Chunxiao Wang, PhD, Binoj Nair, PhD, Hui Liu, MD, PhD, Donald E. Tsai, MD, PhD and Anthony R. Mato, MD, MSCE

1112 The Potential Role of ANKRD36 in Immune Thrombotic Thrombocytopenic Purpura
Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I
Symposia: Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Aria Bales, B.A., Liang Zheng, Ph.D., Antonia Bignotti, B.A., Mark Cunningham, M.D. and X. Long Zheng, MD, PhD

1412 A Pilot Study of Azacitidine as Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
Session: 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Symposia: Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Erin Guest, MD, John Kairalla, PhD, Meenakshi Devidas, PhD, MBA, Emily Hibbitts, MS, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Holly Kubaney, MSN, RN, PPCNP-BC, CPHON, Amanda August, PharmD, Melinda Pauly, MD, Daniel Wechsler, MD, PhD, Rodney R. Miles, MD, PhD, Joel M. Reid, PhD, Cynthia Kihei, BSN, Lia Gore, Elizabeth A. Raetz, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD and Patrick A. Brown, MD

1423 Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis by Disease Risk Subgroups
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Tara L. Lin, MD, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, MD, PhD, MS, Eric S. Winer, MD, Stefan Faderl, Vijayalakshmi Chandrasekaran, Divya Chakravarthy, Ronald S. Cheung and Vinod A. Pullarkat, MD

1436 V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia by FLT3 Mutation Type
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Symposia:  Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
James McCloskey, MD, Vinod A. Pullarkat, MD, Gabriel N. Mannis, MD, Tara L. Lin, MD, Stephen A Strickland, MD, MSC, Amir T. Fathi, MD, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung and Mark J. Levis, MD

1472 Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Danielle C. Kirkey, MD, Xiaoying Wu, PhD, Rhonda E. Ries, MA, Tiffany A. Hylkema, BS, Yanling Liu, PhD, Pandurang Kolekar, PhD, Quang Tran, PhD, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Todd A. Alonzo, PhD, Katherine Tarlock, MD, Robert Eisenman, PhD and Soheil Meshinchi, M.D., Ph.D.

1496 Prognosis of NF1 Mutations in Acute Myeloid Leukemia
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Joshua Tatarian, Stephen Hyter, PhD, Andrew K. Godwin, PhD, Daniel Farrell, MD, Tara L. Lin, MD and Haitham Abdelhakim, MD

1711 Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Vikas Gupta, MD, FRCP, FRCPath, Abdulraheem Yacoub, MD, Srdan Verstovsek, MD, PhD, Ruben Mesa, MD, FACP, Claire N. Harrison, DM, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, H. Joachim Deeg, MD, Salman Fazal, MD, Lynda Foltz, Ryan J. Mattison, MD, Carole B. Miller, MD, Vinod Parameswaran, MD, Patricia Martin-Regueira, MD, Christopher Hernandez, MSc, Jia Wang and Moshe Talpaz, MD

1797 Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I
Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Nirav N. Shah, MD, Michael L. Wang, MD, Jennifer R. Brown, MD, PhD, Krish Patel, MD, Jennifer A. Woyach, MD, William G. Wierda, MD, PhD, Chaitra S. Ujjani, MD, Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, Pier Luigi Zinzani, MD, PhD, Alvaro J. Alencar, MD, Thomas Gastinne, MD, Paolo Ghia, MD, PhD, Nicole Lamanna, MD, Marc Hoffmann, MD, Manish R. Patel, MD, Ian W. Flinn, MD PhD, James N. Gerson, MD, Shuo Ma, MD, Catherine C. Coombs, MD, Chan Yoon Y. Cheah, MD, Ewa Lech-Marańda, MD, PhD, Bita Fakhri, MD, MPH, Won-Seog Kim, Minal A. Barve, MD, Jonathon B. Cohen, MD, MS, Wojciech Jurczak, MD, PhD, Talha Munir, MBBS, MRCP, FRCPath, PhD, Meghan C. Thompson, MD, Lindsey E. Roeker, MD, Katherine Bao, PhD, Nicholas A. Cangemi, BS, Jennifer F. Kherani, MD, Richard A. Walgren, MD, PhD, Hongmei Han, MS, Amy S. Ruppert, PhD and Anthony R. Mato, MD, MSCE

1862 Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Aytaj Mammadzadeh, Fulei Peng, MD, Shebli Atrash, MD, Hamza Hashmi, MD, Meera Mohan, MD, Omar Alkharabsheh, MBBS, Aimaz Afrough, MD, Wei Cui, MD, Zahra Mahmoudjafari, PhD and Al-Ola Abdallah, MD

1918 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I
Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Sagar Lonial, MD, Al-Ola Abdallah, MD, Faiz Anwer, MD, Ashraf Z. Badros, MD, Manisha Bhutani, MD, Abdullah Khan, MBBS, MSc, Brea Lipe, MD, Albert Oriol, Darrell White, MD, Michael Amatangelo, PhD, Kexin Jin, Mark Masin, Vi Nguyen, Alpesh Amin, Paulo Maciag, MD PhD and Niels WCJ Van De Donk, MD

2000 Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Amitkumar Mehta, MD, Umar Farooq, MD, Andy Chen, MD, PhD, Joseph P. McGuirk, DO, Thomas Ly, PhD, Lilly Wong, PhD, Sarah Cooley, MD, Bahram Valamehr, Rebecca Elstrom, MD, Yu-Waye Chu, MD and Jae H Park, MD

2027 Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Hamza Hashmi, MD, Doris K. Hansen, MD, Lauren C. Peres, PhD, MPH, Omar Alexis Castaneda Puglianini, MD, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP, Gabriel De Avila, BS, Surbhi Sidana, MD, Leyla O. Shune, MD, Douglas W. Sborov, MD, James Davis, PharmD, Charlotte B Wagner, PharmD, M. Hakan Kocoglu, MD, Shebli Atrash, MD10, Peter M. Voorhees, MD, Gary Simmons, DO, Christopher J. Ferreri, MD, Nilesh Kalariya, Aishwarya Sannareddy, MBBS, Danai Dima, MD, Jack Khouri, MD, Joseph P. McGuirk, DO, Frederick L. Locke, MD, Rachid C. Baz, MD, Krina Patel, MD, MSc and Melissa Alsina, MD

2033 Peripheral Blast Count at Apheresis Acts Independent of Disease Burden as a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Vanessa A Fabrizio, MD, Kristen Miller, MS, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L. Phillips, MD, Jenna Rossoff, MD, Heather E Stefanski, MD, Julie Talano, MD, Amy Moskop, MD, MS, Susanne H.C. Baumeister, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle L. Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Rachel Wilcox, Vasant Chinnabhandar, MD, MBBS, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD, Amy K. Keating, MD, Michael R Verneris, MD and Liora M. Schultz, MD

2211 Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
Session: 902. Health Services and Quality—Lymphoid Malignancies: Poster I
Symposia: Health Services and Quality—Lymphoid Malignancies 
Program: Oral and Poster Abstracts
Time: 5:30 PM-7:30 PM
Location: Hall D (Ernest N. Morial Convention Center)
Tommy Etekal, Kelly Koehn, MD, Douglas W. Sborov, MD, Brian McClune, DO, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, MD, Samer Al Hadidi, MD, MSc, Al-Ola Abdallah, MD, Aaron M Goodman and Ghulam Rehman Mohyuddin, MD

Sunday, December 11, 2022
422 Distinct Latent Trajectory Phenotypes of Left Ventricular Function Associated with Differential Survival Among Children Treated for Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia
Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 9:30 AM-11:00 AM
Location: La Nouvelle Orlens Ballroom AB (Ernest N. Morial Convention Center)
Kelly D. Getz, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Yimei Li, PhD, Kasey J Leger, MD, MSc, Jessica A. Pollard, MD, Dava Szalda, MD MSHP, Lillian Sung, MD, PhD, Todd M. Cooper, DO, Edward A. Kolb, MD, Alan S. Gamis, MD, MPH, Bonnie Ky, MD and Richard Aplenc, MD, PhD

554 Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL
Symposia: Aggressive Lymphomas: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 12 PM-1:30 PM
Location: R02-R05 (Ernest N. Morial Convention Center)
Ajay Major, MD, MBA, Jovian Yu, MD, MS, Navika D. Shukla, MD, Rachel Treitman, BS, Manali K. Kamdar, MD, Bradley M. Haverkos, MD, MS, MPH, James Godfrey, MD, Melissa A. Babcook, MD, PhD, Timothy J. Voorhees, MD, MSc, Sophie G Carlson, MD, Daria Gaut, MD, Caspian Oliai, MD, MS, Jason T. Romancik, MD, Allison Winter, MD, Brian T. Hill, MD, PhD, Radhika Bansal, MBBS, Jose C. Villasboas, MD, Imran A. Nizamuddin, MD, Reem Karmali, MD, MSc, Lindsey A. Fitzgerald, MD, Deborah M. Stephens, DO, Priyanka A. Pophali, MD, Asaad Trabolsi, MD, Jonathan H. Schatz, MD, Marie Hu, MD, Veronika Bachanova, MD, PhD, Michael J Slade, MD, MS, Nathan Singh, MD, Nausheen Ahmed, MBBS, Joseph P. McGuirk, DO, Michael R. Bishop, MD, Peter A. Riedell, MD and Justin Kline, MD

608 Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial Clinically Relevant Abstract
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological IV
Symposia: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 4:30 PM-6:00 PM
Location: 278-282 (Ernest N. Morial Convention Center)
Martin Dreyling, MD, Michael Dickinson, MD, Joaquin Martinez Lopez, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, MPH, Julio Chavez, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie Jose Kersten, MD, PhD, Charalambos Andreadis, MD, MSCE, Peter A. Riedell, MD, Phoebe Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Jose A. Perez-Simon, MD, PhD, Andy Chen, MD, PhD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andrés J M Ferreri, MD, Takanori Teshima, M.D., Ph.D., Piers E.M. Patten, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, MD, Pier Luigi Zinzani, MD, PhD, Ram Malladi, MD, Ines Paule, Aiesha Zia, Rakesh Awasthi, PhD, Xia Han, MS, Davide Germano, Darragh O'Donovan, PhD, Roberto Ramos, MD, Aisha Masood, MD, Catherine Thieblemont, MD, PhD, Nathan H. Fowler, MD and Stephen J. Schuster, MD

461 ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological II
Symposia: Myelodysplastic Syndromes – Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 4:30 PM-6:00 PM
Location: R06-R09 (Ernest N. Morial Convention Center)
Guillermo Garcia-Manero, MD, Kimo Bachiashvili, MD, Harshad Amin, MD, Elie Traer, MD, PhD, Daniel A. Pollyea, MD, David A. Sallman, MD, Aref Al-Kali, MD, Larry D. Cripe, MD, Jesus G Berdeja, MD, Elizabeth A. Griffiths, MD, Sanjay R Mohan, MD, MSCI, Yuri Sano, MD, Aram Oganesian, PhD, Harold N. Keer, MD, PhD and Abdulraheem Yacoub, MD

657 Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
Session: 705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies 
Program: Oral and Poster Abstracts
Time: 4:30 PM-6:00 PM
Location: Hall E (Ernest N. Morial Convention Center)
Michael Scordo, MD, Jessica R. Flynn, MS, Sean M. Devlin, PhD, Mithat Gonen, PhD, Allison Parascondola, BA, Ana Alarcon Tomas, MD, Roni Shouval, MD, PhD, Jamie Brower, MS, David L. Porter, MD, Stephen J. Schuster, MD, Veronika Bachanova, MD, PhD, Joseph E. Maakaron, MD, Richard T. Maziarz, MD, Loretta J. Nastoupil, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, Andrew Ip, MD, MSc, Lori A. Leslie, MD, Michael R. Bishop, MD, Peter A. Riedell, MD and Miguel-Angel Perales, MD

659 Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-line (2L) ZUMA-7 Study
Session: 705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies 
Program: Oral and Poster Abstracts
Time: 4:30 PM-6:00 PM
Location: Hall E (Ernest N. Morial Convention Center)
Armin Ghobadi, MD, Javier Munoz, MD, MS, MBA, Jason Westin, MD, Frederick L. Locke, MD, David B. Miklos, MD, PhD, Aaron P. Rapoport, MD, Miguel-Angel Perales, MD, Patrick M. Reagan, MD, Joseph P. McGuirk, DO, Caron A. Jacobson, MD, Marie José Kersten, MD, PhD, Irit Avivi, MD, Andrew Peng, MS, Marco Schupp, MD13*, Christina To, MD and Olalekan O. Oluwole, MBBS

2433 The Mechanism of Antibody-Mediated Inhibition of ADAMTS13 in Immune Thrombotic Thrombocytopenic Purpura
Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II
Symposia: Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Chan Meng, MD, Konstantine Halkidis, MD, PhD, Szumam Liu, Ph.D., Don L. Siegel, M.D., Ph.D. and X. Long Zheng, MD, PhD

2457 Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo
Session: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II
Symposia: Coagulation and Fibrinolysis: Basic and Translational 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Wenjing Cao, Aria Bales, B.A., Antonia Bignotti, B.A., Noritaka Yada, Liang Zheng, PhD, Lindsey George, M.D., Denise E. Sabatino, PhD, Marie Scully, MD, Rodney M. Camire, Ph.D. and X. Long Zheng, MD, PhD

2690 Desensitization to Pegaspargase in Children with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Is Safe and Does Not Require Intensive Care – a Single Center Experience
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II
Symposia: Acute Lymphoblastic Leukemias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Keith J August, MD, MS, Tristan Flatt, DO, Joy M. Fulbright, MD, Alan S. Gamis, MD, MPH, Julia A. Hays, MD, Maxine J Hetherington, MD, Karen Lewing, MD, CPC, Amanda August, PharmD and Erin Guest, MD

2801 Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Adam J. Lamble, MD, Rhonda E. Ries, MA, Alice Dang, Ph.D., Todd A. Alonzo, PhD, Karen Chisholm, Pandurang Kolekar, PhD, Yanling Liu, PhD, Quang Tran, PhD, Todd M. Cooper, DO, Richard Aplenc, MD, PhD, Alan S. Gamis, MD, MPH, Edward A. Kolb, MD10, Xiaotu Ma, PhD and Soheil Meshinchi, M.D., Ph.D.

2819 Single-Cell Transcriptomics Reveals Similarity of Aggressive Infant Acute Lymphoblastic Leukemia Cells to Early Hematopoietic Progenitors
Session: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Symposia: Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Irina Pushel, PhD, Midhat S. Farooqi, MD, PhD, Byunggil Yoo, MS, Kai Tan, PhD, Kathrin M. Bernt, MD and Erin Guest, MD

2842 Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
Session: 621. Lymphomas: Translational—Molecular and Genetic: Poster II
Symposia: Lymphomas: Translational—Molecular and Genetic
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Robert J. Hayashi, Michelle L. Hermiston, MD, PhD, David T. Teachey, MD, Meenakshi Devidas, PhD, MBA, Brent L. Wood, MD PhD, Zhiguo Chen, MS, Robert D Annett, Ph.D., Barbara L Asselin, MD, Keith J August, MD, MS, Steve Y Cho, MD, Kimberly P. Dunsmore, MD, Jason L. Freedman, MD, Paul J. Galardy, MD, Paul Harker-Murray, MD, PhD, Terzah M. Horton, MD, PhD, Alok I Jaju, MD, Allison Lam, BCPS, Yoav H. Messinger, MD, Rodney R. Miles, MD, PhD, Maki Okada, RN, Samir I Patel, MD, Eric S Schafer, MD, Tal Schechter-Finkelstein, MD, Kristin A. Shimano, MD, Neelam Singh, PhD, Amii C. Steele, PhD, Maria Luisa Sulis, MD, Sarah L Vargas, PhD, Stuart S. Winter, MD, Charlotte Wood, CCRP, Patrick A Zweidler-McKay, MD, PhD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Elizabeth A. Raetz, MD, Catherine M Bollard, MD and Carl Allen, MD

3187 Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II
Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Evguenia Ouchveridze, MD, Chandandeep Singh, MD, Shebli Atrash, MD, Barry Paul, MD, MS, Meera Mohan, MD, Omar Alkharabsheh, MBBS, Aimaz Afrough, MD, Wei Cui, MD, Zahra Mahmoudjafari, PhD, Al-Ola Abdallah, MD and Hamza Hashmi, MD

3240 Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II
Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Al-Ola Abdallah, MD, Andrew J Cowan, MD, Xavier Leleu, MD, PhD, Cyrille Touzeau, Brea Lipe, MD, Eva Medvedova, MD, Caitlin Costello, MD, Jens Hillengass, MD, PhD, P. Leif Bergsagel, MD, Raya Mawad, MD, Henning Schade, MD, Daniel Morillo Giles, Albert Oriol, MD, Yifah Yaron, Patrick P Ng and Sumit Madan, MD

3246 Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II
Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Ajay K. Nooka, MD, MPH, FACP, Adam Cohen, MD, Hans C. Lee, MD, Ashraf Z. Badros, MD, Attaya Suvannasankha, MD, Natalie Callander, MD, Al-Ola Abdallah, MD, Suzanne Trudel, MD, Ajai Chari, MD, Edward Libby, MD, Maria Chaudhry, MD, Malin Hultcrantz, MD, PhD, Martin Kortuem, Paul G. Richardson, MD, Rakesh Popat, Douglas W. Sborov, MD, Shawn Hakim, PhD, Eric Lewis, MD, Bharat Bhushan, MSc, Boris Gorsh, PharmD, Ira Gupta, MD, Joanna Opalinska, MD and Sagar Lonial, MD

3323 Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Joseph P. McGuirk, DO, Sunil H Abhyankar, MD, Trishna Goswami, MD, Rupal Soder, PhD, Mariska ter Haak, Tyce Bruns, Samantha Langford Youngblood, BS and Lawrence S. Lamb Jr., PhD

3335 A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies 
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Miguel-Angel Perales, MD, Sairah Ahmed, MD, Saurabh Dahiya, MD, Peter A. Riedell, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, Sohail A. Chaudhry, MD, Zachary Lee, PharmD, Stanley Dai, Neha Dixit, PhD, Christie Fanton, PhD, Mario Q. Marcondes, MD, PhD, Jonathan Zalevsky, PhD, Mary A. Tagliaferri, MD and Cameron J. Turtle, MBBS, PhD

3579 Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster II
Symposia: Outcomes Research—Lymphoid Malignancies  
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Agrima Mian, MBBS, MD, Wei Wei, MSc, Rajshekhar Chakraborty, MBBS, Jean C. Yi, PhD, Jaime M. Preussler, MS, Brian T. Hill, MD, PhD, Jan Cerny, MD, PhD, Abhinav Deol, MD, Theresa E. Hahn, PhD, Shahrukh K. Hashmi, MD, MPH, Samantha Jaglowski, MD, MPH, Heather S. L. Jim, PhD, Nandita Khera, MD, MPH, Alison W. Loren, MD, Joseph P. McGuirk, DO, Bipin N. Savani, MD, Patrick Stiff, MD, Joseph P. Uberti, M.D., Ph.D., Victoria Whalen, B.S., John R. Wingard, MD, Jana Reynolds, MD, Shernan G Holtan, MD, William A. Wood, MD, MPH, K. Scott Baker, MD, MS, Karen L. Syrjala, PhD, Betty K. Hamilton, MD and Navneet S. Majhail, MD.

3605 Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster II
Symposia: Outcomes Research—Lymphoid Malignancies  
Program: Oral and Poster Abstracts
Time: 6:00 PM-8:00 PM
Location: Hall D (Ernest N. Morial Convention Center)
Polina Bellman, MD, Wei Cui, MD, Zahra Mahmoudjafari, PhD, Shebli Atrash, MD, Barry Paul, MD, MS, Hamza Hashmi, MD, Rajesh Banderudrappagari, Leyla O. Shune, MD, Al-Ola Abdallah, MD and Nausheen Ahmed, MD

Monday, December 12, 2022
702 Using Spatial Transcriptomics to Reveal Fetal Liver Hematopoietic Stem Cell-Niche Interactions
Session: 506. Bone Marrow Microenvironment: Extrinsic Regulators of Hematopoiesis
Symposia: Bone Marrow Microenvironment 
Program: Oral and Poster Abstracts
Time: 10:30 AM-12:00 PM
Location: 260-262 (Ernest N. Morial Convention Center)
Ruochen Dong, PhD, BM, Jonathon Russell, Hua Li, Seth Malloy, Kate Hall, Kaitlyn Petentler, Allison Scott, Cathy Mckinney, Sarah E Smith, Yongfu Wang, Anoja Perera, Sean McKinney, Brian Slaughter, Jay Unruh, Xi C He and Linheng Li, PhD

714 Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance
Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Time: 10:30 AM-12:00 PM
Location: 275-277 (Ernest N. Morial Convention Center)
Hongtao Liu, MD, PhD, Elad Sharon, MD, MPH, Theodore G. Karrison, PhD, Yuanyuan Zha, PhD, Noreen Fulton, BS, Howard Streicher, MD, Kendra Sweet, MD, George Yaghmour, MD, Jane Jijun Liu, MD, Brian A. Jonas, MD, PhD, Aaron D. Schimmer, MD, PhD, Steven Grant, MD, Amer M. Zeidan, MD, Gerhard C. Hildebrandt, MD, Christopher S. Hourigan, MD PhD, Christopher H. Lowrey, MD, Ryan J. Mattison, MD, Neil Palmisiano, MD, MS, Amandeep Salhotra, MD, Dimitrios Tzachanis, MD, PhD, Maria R. Baer, MD, Tara L. Lin, MD, Prapti Patel, MD, Helen Chen, MD, Walter M. Stadler, MD, Olatoyosi Odenike, MD, Richard A. Larson, MD, Thomas F. Gajewski, MD, PhD and Wendy Stock, MD

757 Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions
Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials
Program: Oral and Poster Abstracts
Time: 10:30 AM-12:00 PM
Location: 288-290 (Ernest N. Morial Convention Center)
Shaji K Kumar, MD, Melissa Alsina, MD, Betsy Laplant, MS, Ashraf Z. Badros, MD, Al-Ola Abdallah, MD, Rafat Abonour, MD, Erik J Asmus, Binod Dhakal, MBBS, Cara A. Rosenbaum, MD, Daniel Egan, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD, PhD and Brian G.M. Durie, MD

766 Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
Session: 705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies 
Program: Oral and Poster Abstracts
Time: 10:30 AM-12:00 PM
Location: 393-396 (Ernest N. Morial Convention Center)
Christopher J. Ferreri, MD, Michelle A.T. Hildebrandt, PhD, Hamza Hashmi, MD, Leyla O. Shune, MD, Joseph P. McGuirk, DO, Douglas W. Sborov, MD, Charlotte B Wagner, PharmD, M. Hakan Kocoglu, MD, Shebli Atrash, MD, Peter M. Voorhees, MD, Jack Khouri, MD, Danai Dima, MD, Aimaz Afrough, MD, Aishwarya Sannareddy, MBBS, Gary Simmons, DO, James Davis, PharmD, Nilesh Kalariya, Lauren C. Peres, PhD, MPH, Melissa Alsina, MD, Frederick L. Locke, MD, Surbhi Sidana, MD, Doris K. Hansen, MD, Krina Patel, MD, MSc and Omar Alexis Castaneda Puglianini, MD

834 A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML
Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies 
Program: Oral and Poster Abstracts
Time: 2:45 PM-4:15 PM
Location: R02-R05 (Ernest N. Morial Convention Center)
Eytan Stein, MD, Sheng F Cai, MD, PhD, Ying Huang, MS, MA, Andrew Dunbar, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William G. Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti A. Patel, MD, Matthew C. Foster, MD, Michael M. Boyiadzis, MD, Robert H. Collins, M.D., Jordan Chervin, Abigail B. Shoben, PhD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Timothy Chen, PhD, Ashley O. Yocum, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, MD, Uma Borate, MD, Amy Burd, PhD29, John C. Byrd, MD and Ross L. Levine, MD

874 Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II
Symposia: Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
Program: Oral and Poster Abstracts
Time: 2:45 PM-4:15 PM
Location: 393-396 (Ernest N. Morial Convention Center)
Peter Westervelt, MD PhD, Partow Kebriaei, MD, Mark Juckett, MD, Andrew S. Artz, MD, MS, Onyee Chan, MD, Philip L. McCarthy, MD, Sherif S Farag, MD, PhD, Anurag K. Singh, MD, Eytan Stein, MD, Jeffrey Humphrey, MD, William Baeder, MPH, Ji Hyun Lee, MD, MPH, Alison Occhiuti, MS, Jeanie Tang, BS, David Santos, BS10*, Kirk Bertelsen, PhD1, Balaji Mahender, BPharm, MS, Nicole Henry, BSN, RN and Shawn Rose, MD, PhD

3807 Netosis and the Formation of Neutrophil Extracellular Traps (NETs) in Patients with Severe and Critical COVID-19 May Contribute to Disease Progression and Thrombosis
Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III
Symposia: Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Noritaka Yada, Quan Zhang, Antonia Bignotti, B.A., Liang Zheng, Ph.D., Zhan Ye, M.D., Ph.D. and X. Long Zheng, MD, PhD

3846 Characterization of Dynamic Niche Signaling Modules during Embryonic Hematopoietic Development Using Spatial Transcriptomics
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Symposia: Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Xinjian Mao, PhD, Ning Zhang, PhD, Kate Hall, Kaitlyn Petentler, Allison Scott, Seth Malloy, Fang Liu, Kevin Ferro, Jessica Bell, Erin Hamilton, Jeffrey Haug, Yongfu Wang, Hua Li, Anoja Perera, Jay Unruh, Brian Slaughter, Xi C He, Nancy Speck, PhD and Linheng Li, PhD

4009 Premedication and Therapeutic Drug Monitoring (TDM) for Pegaspargase: A Prospective Multicenter Multi-Ethnic Study of Pediatric and Adolescent Patients
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Symposia: Acute Lymphoblastic Leukemias: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Van T Huynh, MD, Sonia Morales, MD, Anurag K. Agrawal, MD, Christine L. Phillips, MD, Keith J August, MD, MS, Erin Guest, MD, Beth Apsel Winger, MD, PhD, Catherine Aftandilian, MD, Janel R. Long-Boyle, PharmD, PhD, Kirsten Kasper, BA, Keri Zabokrtsky, MS and Carol Hwang Lin, MD

4091 A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Elad Sharon, MD, MPH, Anne Caldwell, Wei Wei, MD, Abdulraheem Yacoub, MD, Yazan F. Madanat, MD, Joshua F. Zeidner, MD, Jessica K. Altman, MD, Olatoyosi Odenike, MD, Swaroopa Yerrabothala, MD, Tibor Kovacsovics, MD, Nikolai A. Podoltsev, MD, PhD, Stephanie Halene, MD, Richard F. Little, MD, MPH, Richard Piekarz, MD, PhD, MS, BA, Steven D. Gore, MD, Tae Kon Kim, MD and Amer M. Zeidan, MD

4085 A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Joshua F. Zeidner, MD, Matthew C. Foster, MD, Mary Johnson, Ying Huang, MS, MA, Ronan T. Swords, MD, Eytan Stein, MD, James M. Foran, MD, Maria R. Baer, MD, Wendy Stock, MD, Yazan F. Madanat, MD, Tibor Kovacsovics, MD, Rebecca L. Olin, MD, William G. Blum, MD, Gary J. Schiller, MD, Tara L. Lin, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Emily K Curran, MD, Nyla A. Heerema, PhD, Molly Martycz, Leonard Rosenberg, PhD RPh, Sonja Marcus, MPH, Ashley O. Yocum, PhD, Timothy Chen, PhD, Mona Stefanos, Franchesca Druggan, MSc, Amy Burd, PhD, Ross L. Levine, MD, Brian J. Druker, Uma Borate, MD, John C. Byrd, MD and Alice S. Mims, MD

2759 Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Uma Borate, MD, Rui Li, MPH, Ying Huang, MS, MA, Ronan T. Swords, MD, Elie Traer, MD, PhD, Eytan Stein, MD, James M. Foran, MD, Maria R. Baer, MD, Vu H. Duong, MD, MS, Wendy Stock, MD, Olatoyosi Odenike, MD, Prapti Patel, MD, Robert H. Collins, M.D., Yazan F. Madanat, MD, Tibor Kovacsovics, MD, Michael W. Deininger, MD, PhD, Catherine Smith, MD, Rebecca L. Olin, MD, Martha L. Arellano, MD, William G. Blum, MD, Gary J. Schiller, MD, Tara L. Lin, MD, Matthew C. Foster, MD, Michael M. Boyiadzis, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Emily K Curran, MD, Nyla A. Heerema, PhD, Theophilus J Gana, MD PhD, Molly Martycz, Leonard Rosenberg, PhD RPh, Sonja Marcus, MPH, Ashley O. Yocum, PhD, Timothy Chen, PhD, Mona Stefanos, Franchesca Druggan, MSc, Amy Burd, PhD, Ross L. Levine, MD, Brian J. Druker, John C. Byrd, MD and Alice S. Mims, MD

2760 Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Justin Watts, MD, Michael Maris, MD, Tara L. Lin, MD, Prapti Patel, MD, Yazan F. Madanat, MD, Christopher R. Cogle, MD, Gautam Borthakur, MD, Dirk Huebner, MD, Noor Khaskhely, MD, Lynn Bonham, PhD, Monica Massaro, MPH, Daphne Taylor, CPA, Caroline Taromino, MBA and Alice S. Mims, MD

4133 A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Jason E Farrar, MD, Jenny L. Smith, MSc, MEd, Megan Othus, PhD, Benjamin J. Huang, MD, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Tiffany A. Hylkema, BS, Era L Pogosova-Agadjanyan, BS, Sneha Challa, MS, Amanda R. Leonti, MS, Timothy I. Shaw, PhD, Timothy Junius Triche Jr., PhD, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Xiaotu Ma, PhD, Derek Stirewalt, MD, Todd A. Alonzo, PhD and Soheil Meshinchi, M.D., Ph.D.

4264 Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
Symposia: Aggressive Lymphomas: Prospective Therapeutic Trials
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Jason Westin, MD, Alejandro Martín García-Sancho, MD, PhD, Marc Hoffmann, MD, Theodoros P. Vassilakopoulos, MD, Su-Peng Yeh, MD, Argyrios Gkasiamis, MD, Poliana Patah, Arpankumar Patel, Ju Li, PhD and Grzegorz S. Nowakowski, MD

4357 Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Chen Zhang, MD, Douglas Tremblay, MD, John Magnotti, PhD, Lukas Ronner, MD MSCR, Nikolai A. Podoltsev, MD, PhD5, Jason Gotlib, MD, MS6, Mark L. Heaney, MD7, Andrew Kuykendall, MD, Casey L. O'Connell, MD, Angela G Fleischman, MD, PhD, Ruben Mesa, MD, FACP, Abdulraheem Yacoub, MD, John Mascarenhas, MD and Jamile M. Shammo, MD

4357 Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Chen Zhang, MD, Douglas Tremblay, MD, John Magnotti, PhD, Lukas Ronner, MD MSCR, Nikolai A. Podoltsev, MD, PhD5, Jason Gotlib, MD, MS6, Mark L. Heaney, MD7, Andrew Kuykendall, MD, Casey L. O'Connell, MD, Angela G Fleischman, MD, PhD, Ruben Mesa, MD, FACP, Abdulraheem Yacoub, MD, John Mascarenhas, MD and Jamile M. Shammo, MD

4368 A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Kristen M. Pettit, Harinder Gill, MD, MBBS, FRCP, FRCPath, Abdulraheem Yacoub, MD, Terrence Bradley, MD, Aaron T. Gerds, MD, MS, Maciej Tatarczuch, BMBS, Jake Shortt, FRACP, FRCPA, PhD, Natasha Joan Curtin, MD, FRACP, FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Adam J Mead, MD PhD, Joachim R Göthert, MD, Steffen Koschmieder, Matt Reyer, PhD, Benjamin Siranosian, PhD, Georges Natsoulis, Ph.D., William S Stevenson, MBBS, PhD, FRACP, FRCPA, Joanne Ewing, MD, PhD, Joseph M. Chacko, MD, MBBS, BSc, FRCP, FRCPath, Elisa Rumi, Anna B. Halpern, MD, Francesca Palandri, PhD, MD, Nicola Vianelli, MD, Francesco Passamonti, MD, Ruben Mesa, MD, FACP, Monia Marchetti, Claire N. Harrison, DM, Alessandro M. Vannucchi, Justin Watts, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Moshe Talpaz, MD and Hugh Young Rienhoff Jr., MD

4562 Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III
Symposia: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
James E. Hoffman, MD, Brea Lipe, MD, Jason Melear, MD, Michaela Liedtke, MD, Mark A. Schroeder, MD, Ruben Niesvizky, MD, Christopher Strouse, MD, Christopher A. Yasenchak, MD, Damian J. Green, MD, Jeremy Sauer, PhD, Yinghui Wang, MS, Phoenix Ho, MD and Al-Ola Abdallah, MD

4629 CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Joseph P. McGuirk, DO, Constantine S. Tam, Nicolaus Kröger, MD, Peter A. Riedell, MD, Hemant S. Murthy, MD, Phoebe Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Joseph E. Maakaron, MD, Edmund K. Waller, MD, PhD, Farrukh T. Awan, M.D., Paul J. Shaughnessy, MD, Armin Ghobadi, MD, Michael R. Bishop, MD, Ana Alfonso-Pierola, MD, PhD, Michael Dickinson, MD, Praveen Ramakrishnan Geethakumari, MD, MS, Ainsley Ross, MPH, William Stevens, MS, Huansheng Xu, PhD, Anna Ma, MS, Sarah Beaussant Cohen, MD, Richard T. Maziarz, MD and Carlos Bachier, MD

4659 Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Surbhi Sidana, MD, Lauren C. Peres, PhD, MPH, Hamza Hashmi, MD, Hitomi Hosoya, MD, PhD, Christopher J. Ferreri, MD, Shebli Atrash, MD, Jack Khouri, MD, Peter M. Voorhees, MD, Danai Dima, MD, Gary Simmons, DO, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, MD, MS, Sally Arai, MD, David B. Miklos, MD, PhD, Charlotte B Wagner, PharmD, James Davis, PharmD, Douglas W. Sborov, MD, Taiga Nishihori, MD, Melissa Alsina, MD, Frederick L. Locke, MD, Rebecca Gonzalez, PharmD, BCOP, M. Hakan Kocoglu, MD, Aishwarya Sannareddy, MBBS, Aimaz Afrough, MD, Joseph P. McGuirk, DO, Leyla O. Shune, MD, Krina Patel, MD, MSc and Doris K. Hansen, MD

4662 Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
John C. Molina, MD, MEd, Vasant Chinnabhandar, MD, MBBS, Vanessa A Fabrizio, MD, Michael Kunicki, Holly Pacenta, MD, Jenna Rossoff, MD, Heather E Stefanski, MD, Julie Talano, MD, Amy Moskop, MD, MS, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Christina Baggott, RN, PhD, Muna Qayed, MD, MSc, Michelle L. Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy K. Keating, MD, Susanne H.C. Baumeister, MD, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD, Liora M. Schultz, MD and Stephanie M. Smith, MD

4674 Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Anthony J Ross, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine Philips, Jenna Rossoff, MD, Heather E Stefanski, MD, Julie Talano, MD, Amy Moskop, MD, MS, Susanne H.C. Baumeister, MD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Muna Qayed, MD, MSc, Michelle L. Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy K. Keating, MD, Rachel Wilcox, Vanessa A Fabrizio, MD, Vasant Chinnabhandar, MD, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD, Sandra K Althouse, PhD, Shannon L. Maude, MD, PhD, Curtis J Henry, PhD, Liora M. Schultz, MD and Jodi L. Skiles, MD

4677 Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Jack Khouri, MD, Hong Li, MS, Doris K. Hansen, MD, Surbhi Sidana, MD, Leyla O. Shune, MD, Shaun DeJarnette, Faiz Anwer, MD, Douglas W Sborov, Charlotte B Wagner, PharmD, M. Hakan Kocoglu, MD, Shebli Atrash, MD, Peter M. Voorhees, MD, Jason Valent, MD, Lauren C. Peres, PhD, MPH, Vanna Hovanky, Gary Simmons, DO, Danai Dima, MD, Nilesh Kalariya, Aimaz Afrough, MD, Gurbakhash Kaur, MD, Aishwarya Sannareddy, MBBS, Christopher J. Ferreri, MD, James Davis, PharmD, Joseph P. McGuirk, DO, Frederick L. Locke, MD, Rachid C. Baz, MD, Betty K. Hamilton, MD, Melissa Alsina, MD, Craig S. Sauter, MD, Hamza Hashmi, MD and Krina Patel, MD, MSc

4686 PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
Symposia: Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Hillard M Lazarus, MD, Joseph P. McGuirk, DO, Tsila Zuckerman, MD, Leland Metheny, MD, Luis Pineiro, MD, Mark R. Litzow, MD, Scott D. Rowley, MD, Batia Avni, Roni Tamari, MD, Michal Sheleg, PhD, Daniel Rothenstein, PhD, Nitsan Halevy, MD and Jacob M. Rowe, MB, BS.

4703 Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
Symposia: Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Muhammad Umair Mushtaq, MD, Joe S Al-Ramahi, MD, Kevin S Li, Moazzam Shahzad, MD, Sibgha Gull Chaudhary, MD, Ramesh Balusu, PhD, Nausheen Ahmed, MD, Rajat Bansal, MD, Haitham Abdelhakim, MD, Leyla O. Shune, MD, Anurag K. Singh, MD, Sunil H Abhyankar, MD and Joseph P. McGuirk, DO

4709 Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
Symposia: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Sameem Abedin, MD, Mehdi Hamadani, MD, Shernan G Holtan, MD, Gary J. Schiller, MD, Molly Gallogly, MD, PhD, Edmund K. Waller, MD, PhD, Satyajit Kosuri, MD, Sunil H Abhyankar, MD, Sarah M. Anand, MD, Mahasweta Gooptu, MD, Iming Cho, PhD, Simona Reed, PhD, Shih-Yao Lin, MD, PhD, Jesse W Hall, MD and Paul J Martin, MD

4731 Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III
Symposia: Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Najla El Jurdi, MD, Michael Martens, PhD, Claudio G. Brunstein, MD, PhD, Paul O'Donnell, MD, Stephanie J. Lee, MD, MPH, Anita D'Souza, MD, MS, Brent Logan, PhD, Sanghee Hong, MD, Karam Sandhu, Roman M Shapiro, MD, Anurag K. Singh, MD, Mary M. Horowitz, MD, MS and Betty K. Hamilton, MD

4750 Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster III
Symposia: Autologous Transplantation: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Jayanshu Jain, MD, Ghena Khasawneh, MBBS, Hamza Hashmi, MD, Meera Mohan, MD, Zahra Mahmoudjafari, PhD, Wei Cui, MD, Joseph P. McGuirk, DO, Leyla O. Shune, MD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Shebli Atrash, MD

4929 Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL Clinically Relevant Abstract
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III
Symposia: Outcomes Research—Lymphoid Malignancies 
Program: Oral and Poster Abstracts
Time: 6 PM-8 PM
Location: Hall D (Ernest N. Morial Convention Center)
Shakthi Bhaskar, MD, Vivek Patel, MD, David L. Porter, MD, Stephen J. Schuster, MD, Loretta J. Nastoupil, MD, Miguel-Angel Perales, MD, Ana Alarcon Tomas, Michael R. Bishop, MD, Joseph P. McGuirk, DO, Richard T. Maziarz, MD, Andy Chen, MD, PhD, Veronika Bachanova, MD, PhD, Peter A. Riedell, MD and Olalekan O. Oluwole, MBBS

Tuesday, December 13, 2022
LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Session: Late Breaking Abstracts
Program: Oral and Poster Abstracts
Time: 9 AM-10:30 AM
Location: Hall E (Ernest N. Morial Convention Center)
Mark R. Litzow, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Ryan J. Mattison, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Daniel A. Arber, MD, Charles G. Mullighan, MBBS, MD, Cheryl L Willman, MD, Yanming Zhang, MD, Matthew Wieduwilt, MD, Michaela Liedtke, MD, Julie Bergeron, MD, Keith W. Pratz, MD, Shira Dinner, MD, Noelle V. Frey, MD, MS, Steven D. Gore, MD, Bhavana Bhatnagar, DO, Ehab L. Atallah, MD, Geoffrey L. Uy, MD, Deepa Jeyakumar, MD, Tara L. Lin, MD, Richard F. Little, MD, MPH, Selina M. Luger, MD, FRCPC and Martin S. Tallman, MD

December 6, 2022
GS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)
General Session #1
Location: Hall #3
Date: Tuesday, Dec 6, 2:00 - 2:15 PM
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K. 

GS1-04 Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
General Session #1
Location: Hall #3
Date: Tuesday, Dec 6, 2:45 - 3:00 PM
Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. 

GS1-07 Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
General Session #1
Location: Hall #3
Date: Tuesday, Dec 6, 3:30 - 3:45 PM
Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz  PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopolu E, Baar J, Wendt AG, Careny JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. 

PD1-06 Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy
Session: Spotlight Poster Discussion 1 – Racial Outcomes and Disparities
Date: Tuesday, Dec 6, 5:00 PM
Stecklein SR, Yoder R, Salgado R, Staley JM, O'Dea A, Nye L, Elia M, Satelli D, Crane G, McKittrick R, Godwin AK, Khan Q, Sharma P.

P1-13-08 Inhibition of RNA binding protein HuR function sensitizes the TNBC to chemotherapy
Session: Poster Session #1 Treatment - Adjuvant Therapy: Adjuvant Chemotherapy
Date: Tuesday, Dec 6, 5:00 PM
Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L. 

December 7, 2022
P2-11-11 Computer analysis of nuclear morphology with multiple instance learning predicts overall survival for node positive breast cancer patients from SWOG S8814: A blinded validation study
Session: Poster Session #2 Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted
Date: Wednesday, Dec 7, 7:00 AM
Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes DF, Godwin AK, Thonpson AM, Madabhushi A, Pusztai L. 

P2-11-16 Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814
Session: Poster Session #2 Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted
Date: Wednesday, Dec 7, 7:00 AM
Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KS, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A. 

P2-20-11 Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors
Session: Poster Session #2 Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted
Date: Wednesday, Dec 7, 7:00 AM
Werner LR, Helm DE, Tinoco J, Chowanec EI, Holloran SM, Hastings RC, Wei J, Lei G, Yang X-Y, Markiewicz MA, Chalise P, Balko JM, Hartman ZC, Hagan CR. 

HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score
Session: HER2 Low: A Separate Entity Special Session
Location: Hall 3
Date: Wednesday, Dec 7, 9:45 - 11:00 AM
Spring LM, Barlow WE, Bardia A, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. 

P3-07-08    Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)
Session: Poster Session #3 - Treatment - Advanced Disease Treatment: Advanced Endocrine Therapy
Date: Wednesday, Dec 7, 5:00 PM
Tolaney SM, Schmid P, Bardia A, Marmé F, Loirat D, Sharma P, Wang H, Fu O, Verret W, Rugo HS. 

December 8, 2022
PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials
Session: Spotlight Poster Discussion 11 – Improving Outcome for TNBC: New Directions in Immunotherapy
Date: Thursday, Dec 8, 7:00 AM
Sharma P, Stecklein SR, Yoder R, Staley JM, Salgado R, Paré; Conte B, Brasó-Maristany F, O'Dea A, Nye L, Elia M, Satelli D, Crane G, McKittrick R, Khan Q, Godwin AK, Prat A. 

GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Session: General Session #3
Location: Hall 3
Date: Thursday, Dec 8, 9:45 - 10:00 AM
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma CX, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Jolly T, Riley E, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block C, Ko N, Partridge AH, Chen WY, DeMeo MK, Attaya V, Okpoebo A, Liu Y, Gauthier E, Burstein H, Regan MM, Tolaney SM. 

PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Session: Spotlight Poster Discussion 14 - Breast Cancer Risk Modeling
Date: Thursday, Dec 8, 5:00 PM
Mabey B, Hughes E, Probst B, Pederson HJ, Simmons T, Morris B, Hullinger B, Domchek SM, Eng C, Gary M, Klemp J, Mukherjee S, Joseph V, Offit K, Olopade OI, Pruthi S, Kurian AW, Robson ME, Whitworth P, Wagner S, Lanchbury J, Slavin T, Gutin A. 

December 9, 2022
P6-05-06 Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status
Session: Poster Session #4 - Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive Biomarkers for Chemo
Date: Friday, Dec 9, 7:00 AM
Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow WE, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. 

P6-14-08 Epithelial/stromal cross talks that induce malignant transition of human ductal carcinoma in situ
Session: Poster Session #4 - Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive Biomarkers for Chemo
Date: Friday, Dec 9, 7:00 AM
Rastogi A, Behbod F, Navin N, Lin J, Li L, Li H, Godwin AK, Thompson AM, Fields T, Hong Y.

*The below content was pulled from currently available information on ASTRO's website as well as supplied by KU Cancer Center members.

October  23, 2022
2815 Flying over the "No Fly Zone:" Re-Irradiation of Ultracentrally Located Thoracic Tumors Utilizing Hypofractionated Stereotactic Body Radiotherapy
PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH
Category: Lung Cancer/Thoracic Malignancies
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Sunday, Oct 23 4:45 PM
Presenting Author: Crosby D. Rock MD
Authors: C. D. Rock, S. S. Sood, Y. Cao, R. C. Chen, and F. Wang

October 24, 2022
1 NRG RTOG 1005: A Phase III Trial of Hypo Fractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer
Location: Henry B. Gonzalez Convention Center, Stars at Night Ballroom
Date: Monday, Oct 24 1:30 PM
Session: PL 01 - Plenary Session
F. A. Vicini, K. Winter, G. M. Freedman, D. W. Arthur, J. A. Hayman, B. S. Rosenstein, S. M. Bentzen, A. Li, J. Lyons, J. K. Tomberlin, S. A. Seaward, S. Cheston, J. Coster, B. M. Anderson, F. E. Perera, M. M. Poppe, I. A. Petersen, J. G. Bazan Jr, J. Moughan, and J. R. White

SS 11 - GU 2 - New Insights into Post-Prostatectomy Radiotherapy
Location: Henry B. Gonzalez Convention Center, Room 214
Date: Monday, Oct 24 3:00 PM
Session Type: Scientific
Track: Genitourinary Cancer
Discussant: Ronald C. Chen MD, MPH, FASTRO

October  25, 2022
3058 Cervical Spine Setup Reproducibility Using Standard Headrests vs. Custom Headrests in Head and Neck Cancer Patients
PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Tuesday, Oct 25 2:30 PM
Category: Patient Safety
Presenting Author: Truston Bodine MD, PhD
Authors: T. Bodine, K. Guida, G. N. Gan, and C. E. Lominska

October  26, 2022
2665 Assessment of Nutritional and Imaging Biomarkers to Predict PEG Tube Placement in Non-HPV-Associated Head and Neck Patients Undergoing Concurrent Chemoradiotherapy
PQA 09 - Poster Q&A 09 - Head & Neck Cancer and Health Services Research
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 10:30 AM
Category: Head and Neck Cancer
Presenting Author: Ryan Zitter MSc
Authors: R. Zitter, R. Morse, R. G. Ganju, G. N. Gan,  Y. Cao, P. Neupane, K. Kakarala, Y. Shnayder, and C. E. Lominska

3201 Hybrid Proton-Photon Treatment Planning with Fraction Optimization
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Hao Gao, PhD
Authors: W. Li, W. Zhang, Y. Lin, R. C. Chen, and H. Gao

3283 FLASH-Enabled Proton SBRT/SRS via Simultaneous Dose and Dose Rate Optimization (SDDRO)
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Hao Gao PhD
Authors: H. Gao, Y. Lin, G. N. Gan, F. Wang, H. Li, and R. C. Chen

3305 Maximization of Peak-to-Valley Dose Ratio and Normal-Tissue Survival Fraction for Proton Minibeam Radiation Therapy
PQA 10 - Poster Q&A 10 – Physics
Location: Henry B. Gonzalez Convention Center, Exhibit Hall 1
Date: Wednesday, Oct 26 12:30 PM
Category: Radiation and Cancer Physics
Presenting Author: Weijie Zhang PhD
Authors: W. Zhang, W. Li, Y. Lin, F. Wang, R. C. Chen, and H. Gao

*The below content was pulled from currently available information on ASCO's website as well as supplied by KU Cancer Center members. 

June 4, 2022
Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract TPS7069:  Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 297a
Presenter: Tara L. Lin, MD, MS
Authors: Tara L. Lin, Robyn Wood, Tammy Ham, Taegen Sullivan, Sangita Bhattacharyya, Prasad Dandawate, Shrikant Anant, Marianne T Santaguida, Na Zhang, Paul Toren, Roy A. Jensen, John A. Taylor III, Michael Jay Baltezor, Michael Dalton, John McBride, Jay Nicholas Umbreit, William McCulloch, Kathryn Vanderlaag, Joseph Wagner, Scott James Weir

Abstract 7027: A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 258
Authors: Alice S. Mims, Ying Huang, Eric Eisenmann, Daelynn Buelow, Ronan T. Swords, Matthew Charles, Foster, Tara L. Lin, Maria R. Baer, Tibor Kovacsovics, Zeina Al-Mansour, Mona Stefanos, Franchesca Druggan, Timothy Chen, Ashley Yocum, Uma Borate, Brian J. Druker, Amy Burd, Ross L. Levine, Sharyn D. Baker, John C. Byrd

Abstract 7031: Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 262
Authors: Geoffrey L. Uy, Vinod A. Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald Cheung, Tara L. Lin

Abstract 7043: V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 274
Authors: James K. McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen Anthony Strickland, Amir Tahmasb Fathi, Harry Paul Erba, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald Cheung, Mark J. Levis

Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract TPS4195:  Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 162b
Presenter: Anup Kasi MD, MPH

Abstract 4047:  A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 35
Presenter: Weijing Sun, MD, FACP
Authors: Sun, W., Saeed, A., Al-Rajabi, R., Kasi, A., Veermachaneni, N., Al-Kasspooles, M., Baranda, J., Phadnis, M., Godwin, A.K., Olyaee, M., Madan, R., Nagji, A., Williamson, S. A

Poster Session: Symptoms and Survivorship
Abstract 12023: Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221.
Time: June 4, 2022 – 4:30 p.m. CDT
Location: In-Person & On Demand
Poster: 269
Authors: Ciao-Sin Chen, C-S., Zirpoli, G., McCann, S.E., Barlow, W.E., Budd, G.T., Pusztai, L., Hortobagyi, G.N., Godwin, A.K., Thompson, A., Ambrosone, C.B., Stringer, K.A., Hertz, D.L.

Poster Session: Gastrointestinal Cancer - Colorectal and Anal
Abstract 3623: Circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) assessment and recurrence risk in patients undergoing curative intent resection with or without adjuvant chemotherapy in colorectal cancer: A systematic review and meta-analysis.
Time: June 4, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 416
Authors: NA (currently unavailable on website)

Poster Session: Genitourinary Cancer—Kidney and Bladder
Abstract TPS4607: MAIN-CAV: phase III randomized trial of maintenance cabozantinib (cABO) and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001). 
Time: June 4, 2022 – 1:15 p.m. CDT
Location: In-Person & On Demand
Poster: 93b
Authors: Gupta S, Ballman KV, Galsky MD, Morris MJ, Chen R, Chan TM, Dercle L, Wen Y, Sridhar S, Al-Baghadadi T, Yen AE, Grivas P, Tan A, Baghaie S, Rosenberg JE

June 5, 2022
Poster Session: Developmental Therapeutics—Immunotherapy
Abstract 2575:  Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
Time: June 5, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 230
Presenter: Chao Hui Huang, FACP, MD

June 6, 2022
Poster Session: Breast Cancer - Local/Regional/Adjuvant
Abstract 557:  A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.
Time: June 6, 2022 - 8 a.m. CDT
Location: In-Person & On Demand 
Poster: 329
Authors: Elisha Hughes, PhD; Braden Probst, MStat; Holly Jane Pedersen, MD; Timothy Simmons, MStat; Brian Morris, BS; Susan M. Domchek, MD; Charis Eng, MD, PhD; Monique Gary, MD;
Ora Gordon, MD; Jennifer R. Klemp, PhD, MPH; Semanti Mukherjee, PhD; Kenneth Offitt, MD; Olufunmilayo I. Olopade, MD; Mark E. Robson, MD; Joseph Vijai, PhD;
Pat W. Whitworth, MD, FACS, FSSO; Susanne Wagner, PhD; Jerry S. Lanchbury, PhD; Thomas P. Slavin, MD; Alexander Gutin, PhD

Abstract 594: Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (SWOG S0800) Using Image Analysis-Based Tumor Infiltrating Lymphocyte Measurements. 
Time: June 6, 2022 – 8:00 a.m. CDT
Location: In-Person & On Demand
Poster: 365
Authors: Blenman, K., Fanucci, K., Bai, Y., Pelekanou, V., Nahleh, Z.A., Shafi, S., Burela, S., Barlow, W.E., Sharma, P., Thompson, A.M., Godwin, A.K., Rimm, D.L., Hortobagyi, G.N., Pusztai, L.

Poster Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract 10549:  Project BRA: Breast cancer risk assessment.
Time: June 6, 2022 - 1:15 p.m. CDT
Location: In-Person & On Demand 
Poster: 425
Presenter: Lauren Elizabeth Nye, MD
Authors: Lauren E. Nye, Sharla Smith, Catherine J. Knight, Jennifer R. Klemp

Poster Session: Health Services Research and Quality Improvement
Abstract 6542:  Bringing experimental therapeutics clinical trials network (ETCTN) to underrepresented population.
Time: June 6, 2022 – 1:15 p.m. CDT
Location: In-Person & On Demand
Poster: 325
Presenter: Joaquina Celebre Baranda, MD
Authors: Joaquina Celebre Baranda, Gary C. Doolittle, Rahul Atul Parikh, Anup Kasi, Elizabeth Marie Wulff- Burchfield, Benjamin Powers, Robert E. Pluenneke, Marc Steven Hoffmann, Abdulraheem Yacoub, Anwaar Saeed, Larry R. Corum, Tara L. Lin, Weijing Sun, Margaret M. Mooney, Jeffrey Moscow, James H. Doroshow, Brittany Waters, S. Percy Ivy, Steven Gore, Roy A. Jensen

Poster Discussion Session: Breast Cancer—Local/Regional/Adjuvant
Abstract 513: Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
Time: June 6, 2022 - 1:27 p.m. CDT
Location: In-Person & Live Stream | Hall B1
Poster: 285
Presenter: Priyanka Sharma, MD
Authors: Sharma, P., Stecklein, S.R., Yoder, R., Staley, J.M., Schwensen, K., O’Dea, A., Nye, L., Elia, M., Satelli, D., Crane, G., Madan, R., O’Neil, M., Wagner, J., Larson, K., Christa Balanoff, C., Phadnis, M.A., Godwin, A.K., Salgado, R., Khan, Q.J., O’Shaughnessy, J.

Poster Discussion Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract TPS5107: Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Time: June 6, 2022 - 1:15 p.m. CDT
Location: In-Person & On-Demand
Poster: 283a
Authors: Rao A, Heller G, Ryan CJ, VanderWeele DJ, Lewis LD, Tan A, Watt C, Chen RC, Kohli M, Barata PC, Gartrell BA, Grubb R, Dueck AC, Wen Y, Morris MJ. 

On-Demand
Session Type: Publication Only
IV vitamin C with chemotherapy for cisplatin ineligible bladder cancer patients (CI-MIBC) first-stage analysis NCT04046094.
Session Title/Track: Genitourinary Cancer—Kidney and Bladder
Authors: Rahul Atul Parikh, PhD, MBBS | Others TBD (currently unavailable on website)

Acute promyelocytic leukemia: A single institution's experience.
Session Title/Track: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Authors: Joseph Bennett, Tara L. Lin, Priyanka Venkatesh, Heather Jean Male, Kenneth Byrd

Utilizing an innovative digital collaboration tool to impact shared decision making, health equity and trust with a focus on advance care planning for patients with metastatic breast cancer.
Session Title/Track: Symptoms and Survivorship
Authors: NA (currently unavailable on website)

Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.
Session Title/Track: Breast Cancer – Metastatic 
Authors: NA (currently unavailable on website)

Association of pathologic response and survival after peri-operative therapy in resected pancreatic adenocarcinoma: KU cancer center experience.
Session Title/Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Authors: NA (currently unavailable on website)

A multicenter, open-label, phase I/II study of FN-1501 in patients with advanced solid tumors and acute myeloid leukemia.
Session Title/Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Authors: NA (currently unavailable on website)

Efficacy of sacituzumab govitecan based regimen in triple-negative breast cancer: A systematic review.
Session Title/Track: Breast Cancer—Metastatic
Authors: NA (currently unavailable on website)

A randomized phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or hormone receptor positive breast cancer.

Session Title/Track: Oral Abstract Session Breast Cancer-Metastatic

Authors:  Kevin Kalinsky, Melissa K Accordino, Cody Chiuzan, Prabhjot Mundi, Megna S Trivedi, Yelena Novik, Sandra Rie, William Gradishar, Anne O'Dea, Ruth O'Regan, Katherine D Crew, Dawn L Hershman

 

Underline: KUCC Members
Underline & Bold: KUCC Members that Presented

April 8
Session OPO.ET01.01 - Drug Discovery
5306 - IRAK1: A novel TOLLway to target ovarian cancer
Friday, April 8, 2022: Noon - 1 p.m.
David Standing, Sumedha Gunewardena, Afreen A. A. Sayed, Michele T. Pritchard, Harsh B. Pathak, Andrew K. Godwin, Shariska Petersen, Dineo Khabele, Roy A. Jensen, Prasad Dandawate, Scott J. Weir, Shrikant Anant

Session OPO.MCB04.01 - Gene Regulation and Transcription Factors
5725 - HOXA9 demonstrates allelic imbalance in KMT2A-rearranged infant acute lymphoblastic leukemia
Friday, April 8, 2022: Noon - 1 p.m.
Sarah E. Mc Dermott, Byunggil Yoo, Warren A. Cheung, Emily Farrow, Bing Ge, Margaret Gibson, Patrick A. Brown, Erin Guest, Tomi Pastinen, Midhat S. Farooqi

Session OPO.PR02.01 - Clinical Prevention, Early Detection, and Interception
5922 - Clinical validation of a spectroscopic liquid biopsy for early detection of brain cancer
Friday, April 8, 2022: Noon - 1 p.m.
James M. Cameron, Paul M. Brennan, Georgios Antoniou, Holly J. Butler, Loren Christie, Justin J.A. Conn, Tom Curran, Ewan Gray, Mark G. Hegarty, Michael Jenkinson, Daniel Orringer, David S. Palmer, Alexandra Sala, Benjamin R. Smith, Matthew J. Baker

Session OPO.CT02.01 - Phase II Clinical Trials
CT541 - Efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study
Friday, April 8, 2022: Noon - 1 p.m.
Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice Wang, Aaron Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen Oh, Gary Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver


April 9
ED039. The Evolving Crosstalk in the Cancer Stem Cell Niche - Invited Speaker
Saturday, April 9, 2022: 8:30 - 8:50 a.m.
Room 265-268, Convention Center
Linheng Li 


April 10
SY42. The Microenvironment and Immune System in Cancer Stem Cells - Tumor-initiating stem cells shape microenvironment into an immunosuppressive barrier and a pro-tumorigenic niche
Sunday, April 10, 2022: 1:05 - 1:25 p.m.
Room 353-355, Convention Center
Linheng Li

Session PO.MCB11.02 - Cellular Stress Responses 2: Senescence and Unfolded Protein Response
143 / 9 - Novel HSP40 or J domain protein inhibitors that deplete misfolded mutant p53
Sunday, April 10, 2022: 1:30 - 5:00 p.m.
Tomoo Iwakuma, Shigeto Nishikawa, Atsushi Kaida, Atul Ranjan, Alejandro Parrales, Mohamed A. Alalem, David K. Johnson

Session PO.MCB01.02 - Kinases and Phosphatases
157 / 11 - DUSP6 modulates migration and glycolysis in PDAC cells
Sunday, April 10, 2022: 1:30 - 5:00 p.m.
Mariana T. Ruckert, Bailey A. Bye, Michael N. VanSaun, Vanessa S. Silveira

Session PO.TB11.01 - Carcinogenesis
224 / 3 - Effect of Agent Orange and Agent Blue derived carcinogens on bladder cancer cell lines and a murine bladder cancer model
Sunday, April 10, 2022: 1:30 - 5:00 p.m.
Ganeshkumar Rajendron, Erika Abbott, Jeffery Thompson, Shachi Patel, Aaron Barchowsky, Katie Dennis, Benjamin L. Woolbright, John A. Taylor III

PAS03. Personalized Career Conversations - Chairperson
Sunday, April 10, 2022: 5:30 - 7:30 p.m.
Mardi Gras Salon D-E, Marriott
Danny R. Welch


April 11
Session PO.IM01.04 - Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity
1351 / 10 - Lauryn Werner
Monday, April 11, 2022:9:00 a.m. - 12:30 p.m.
Lauryn Rose Werner, Katelin A. Gibson, Merit L. Goodman, Dominika E. Helm, Katherine R. Walter, Sean M. Holloran, Gloria M. Trinca, Richard C. Hastings, Howard H. Yang, Ying Hu, Junping Wei, Gangjun Lei, Xiao-Yi Yang, Rashna Madan, Alfredo A. Molinolo, Mary A. Markiewicz, Prabhakar Chalise, Margaret L. Axelrod, Justin M. Balko, Kent W. Hunter, Zachary C. Hartman, Carol A. Lange, Christy R. Hagan

Session PO.MCB07.01 - Genomic Instability 1
792 / 1 - Knockdown of MK2 in bladder cancer cells increases their radiosensitivity
Monday, April 11, 2022: 9:00 a.m. - 12:30 p.m.
Deri Morgan, Grace Millington, Hanna Smith, Colby Spiess, Kiersten L. Berggren, Xinglei Shen, Gregory N. Gan

Session PO.MCB03.02 - Oncogenes and Tumor Suppressor Genes 2
861 / 21 - Nuclear translocation of Axl during early breast cancer progression
Monday, April 11, 2022: 9:00 a.m. - 12:30 p.m.
Darby R. Graham, Kelly D. Hebert, Emma E. Newton, Angelica M. Gomes, Fariba Behbod, Heather L. Machado

Session PO.MCB01.04 - Growth Factor and Receptors
1529 / 10 - Role of bitter taste receptor in colon cancer
Monday, April 11, 2022: 1:30 - 5:00 p.m.
Krishan Jain, Sangita Bhattacharyya, Afreen Sayed, David Standing, Kathy Benich, Shahid Umar, Shrikant Anant, Scott Weir, Roy Jensen, Prasad Ravindra Dandawate

Session PO.ET03.04 - Breast Cancer Drug Resistance and Novel Targets
1780 / 9 - Functional inhibition of RNA-binding protein HuR reverses chemotherapeutic resistance in triple-negative breast cancer
Monday, April 11, 2022: 1:30 - 5:00 p.m.
Lanjing Wei, Qi Zhang, Cuncong Zhong, Jeffrey Aubé, Danny R. Welch, Xiaoqing Wu, Liang Xu

Session PO.CT01.01 - Phase I Clinical Trials 1
CT134 / 1 - Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs)
Monday, April 11, 2022: 1:30 - 5:00 p.m.
Joaquina Baranda, Michael S. Gordon, Aparna R. Parikh, Huyuan Yang, Gregory K. Pennock, Philip Komarnitsky, Muhammad S. Beg

PAS05. Navigating the Path to a Successful Career in Cancer Research - Mentor
Monday, April 11, 2022: 7:00 - 9:00 p.m.
Acadia Room, Marriott
Danny R. Welch


April 12
Session PO.PR02.02 - Premalignant Lesions, Intervention, and Health Disparities
2207 / 7 - High-dose omega-3 fatty acid supplementation is associated with a decrease in FOXA1 in benign breast tissue
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Carol J. Fabian, Trina Metheny, Teresa A. Phillips, Marsha Danley, Bruce F. Kimler

Session PO.MCB06.01 - Cell Cycle Control and Cell Cycle Regulators as Therapeutic Targets
2299 / 3 - Function of Ewing sarcoma EWSR1 protein in the maintenance of chromosome stability
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Haeyoung Kim, Mizuki Azuma

Session PO.TB04.01 - Cellular and Molecular Processes of Metastasis 1
2419 / 23 - Understanding the role of DCLK1 mediated invadopodia regulation in HNSCC
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Levi K. Arnold, David Standing, Prabhu Ramamoorthy, Harmony Saunders, Thuc Ly, Shrikant Anant, Sufi Thomas

Session PO.TB08.03 - Omics Approaches: Disease Classification, Biomarkers of Response, and Outcome Prediction in Pediatric Oncology
2498 / 8 - Prognostically significant molecular pathways in infants diagnosed with acute lymphoblastic leukemia with KMT2A gene rearrangement
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Sidharth Ramesh, Irina Pushel, Byunggil Yoo, Midhat S. Farooqi, Tomi Pastinen, Patrick Brown, Erin Guest

Session PO.TB08.03 - Omics Approaches: Disease Classification, Biomarkers of Response, and Outcome Prediction in Pediatric Oncology
2503 / 13 - Identification of clinically relevant gene fusions in archived pediatric solid and liquid tumor samples using Arima-HiC sequencing
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Midhat S. Farooqi, Kristin Sikkink, Derek Reid, Tomi Pastinen, Anthony Schmitt, Atif Ahmed

Session PO.TB06.10 - Organ-specific Tumor Microenvironment 2
2539 / 6 - Macrophage derived WNTs regulate immune checkpoint expression and inflammation induced colon cancer
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Subhrajit Saha, Pooja Gupta, Rishi Man Chugh, Ximena Diaz Olea, Tanu Arora, Payel Bhanja

Session PO.TB06.10 - Organ-specific Tumor Microenvironment 2
2558 / 25 - Determining the expression of RNA binding protein Rbm3 in tumor cells and immune cells in the tumor microenvironment in prostate cancer
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Afreen Asif Ali Sayed, David Standing, Prasad Dandawate, Shahid Umar, Roy Jensen, Rahul Parikh, John Taylor, Shrikant Anant

Session PO.CL11.10 - Diagnostic Biomarkers
2805 / 16 - Mass spectrometry detects lower frequency of routine markers and consistent overexpression of novel disease drivers in Barrett's-related esophageal cancer
Tuesday, April 12, 2022: 9:00 a.m. - 12:30 p.m.
Christopher Hartley, Ajay Bansal, Catherine Hagen, Olivia Driscoll, Seyun Oh, Joe Abdo, Sumeet K. Mittal

Session PO.MCB01.05 - GTPase and Ubiquitin Signaling
2979 / 8 – Elevated NRAS expression as a potential driver of DCIS progression to basal-like invasive breast cancer
Tuesday, April 12, 2022: 1:30 - 5:00 p.m.
Ze-yi Zheng, Hanan Elsarraj, Yang Hong, Jonathan T. Lei, Meenakshi Anurag, Yichao Shen, Flora Lo, Long Feng, Zifan Zhao, Xiang H. -F. Zhang, Fariba Behbod, Eric C. Chang

Session PO.MCB02.01 - Non-apoptotic Cell Death / Autophagy
3002 / 9 - Characterization of novel role for Rab27B in autophagy regulation in colorectal cancer
Tuesday, April 12, 2022: 1:30 - 5:00 p.m.
Sahida Afroz, Ranjan Preet, Vikalp Vishwakarma, Dan Dixon

Session PO.CL07.01 - Translational and Clinical Science
3457 / 15 - Rebastinib, a TIE2 antagonist improves chemotherapy response in homologous recombination proficient epithelial ovarian cancer murine models
Tuesday, April 12, 2022: 1:30 - 5:00 p.m.
Vijayalaxmi G. Gupta, Katherine F. Roby, Harsh B. Pathak, Andrew K. Godwin, Sumedha Gunewardena, Dineo Khabele 

Session LBPO.PSPR01 - Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception
LB165 / 9 - Preclinical evaluation of carnosic acid (CA) and rosemary extract standardized to 40% carnosic acid (RE40CA) for the prevention of invasive breast cancer
Tuesday, April 12, 2022: 1:30 - 5:00 p.m.
Yan Hong, Aditi Rastogi, Aryamitra Banerjee, Brandon L. Plattner, Matthew Lindeblad, Alexander V. Lyubimov, Timothy Fields, Seema A. Khan, Altaf Mohammed, Jeremy J. Johnson, Fariba Behbod

Session LBPO.PSPR01 - Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception
LB167 / 11 - Functional extracellular vesicle profiling with nanochips for cancer diagnosis and monitoring
Tuesday, April 12, 2022: 1:30 - 5:00 p.m.
Yong Zeng, Shibo Chen, Yunjie Wen, Liang Xu


April 13
Session PO.TB06.01 - Innervation, ECM, and Cell Surface Receptors
3844 / 16 - COL11A1: A driver of tumor progression and immune evasion in head and neck squamous cell carcinoma (HNSCC)
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Harmony Ivanna Saunders, Levi Arnold, Mary Markiewicz, Sufi M. Thomas

Session PO.TB06.01 - Innervation, ECM, and Cell Surface Receptors
3852 / 24 - The chemokine C-C motif ligand 2 (CCL2) plays an important role in skeletal muscle wasting associated with breast cancer progression
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Nadia Alissa, Wei Bin Fang, Gage Brummer, Marcela Mitchell, John Thyfault, Paige Geiger, Nikki Cheng

Session PO.ET04.01 - Identification of Molecular Targets
3991 / 13 - Ts65Dn Down syndrome mice reveal a potential therapeutic vulnerability in a BBN bladder cancer model and subset of bladder cancer cell lines
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Binh Vo, Erika Abbott, Carolyn J. Vivian, Xena Moore, Ganeshkumar Rajendran, Katie Dennis, Benjamin L. Woolbright, Scott J. Weir, John A. Taylor III

Session PO.ET05.01 - Molecular Pharmacology
4027 / 6 - Dual MEK and AKT inhibition suppresses pancreatic cancer growth and migration
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Jarrid Jack, Alexandra Pierce, Bailey Bye, McKinnon Walsh, Prabhakar Chalise, Michael N. VanSaun

Session PO.IM02.05 - Combination Immunotherapies 1
4173 / 9 - Improve anti-PD-1 immunotherapy response in immunologically cold tumors by harnessing RNA-binding protein HuR
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Qi Zhang, Yang Zhe, Xiaoqing Wu, Lan Lan, Lanjing Wei, Liang Xu

Session PO.IM02.05 - Combination Immunotherapies 1
4187 / 23 - Combined MEK and STAT3 inhibition reprograms the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer
Wednesday, April 13, 2022: 9:00 a.m. - 12:30 p.m.
Vanessa Tonin Garrido, Jashodeep Datta, Xizi Dai, Anna Bianchi, Iago De Castro Silva, Purushottam Lamichhane, Siddharth Mehra, Samara P. Singh, Austin R. Dosch, Oliver Umland, Michael N. VanSaun, Peter J. Hosein, Nagaraj Nagathihalli, Nipun Merchant

PL06. AACR Annual Meeting 2022 Highlights: Vision for the Future – Basic and Translational Research
Wednesday, April 13, 2022: 12:05 p.m. - 12:30 p.m.
Hall B-C, Convention Center
Danny R. Welch

Friday, December 10, 2021
Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?
Time: 11 AM - 2 PM
Location: Centennial 1 (Hyatt Regency Atlanta)
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:  Bone Marrow Failure Syndromes, Diseases
Laura C. Michaelis, MD, The Medical College of Wisconsin Inc., Lindsey Lyle, MS, PA-C, University of Colorado, Andrew T. Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute and Abdulraheem Yacoub, MD, University of Kansas Cancer Center

Saturday, December 11, 2021
1020 Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
1020 Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura
Noritaka Yada, Jingrui Sui, M.D., Ph.D., Liang Zheng, Ph.D. and X. Long Zheng, MD

1268 Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Vinod A. Pullarkat, MD, Mark Levis, MD, Gabriel N. Mannis, MD, Stephen A Strickland, Tara L. Lin, MD, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung and Harry P. Erba

1277 Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Elie Traer, MD, PhD, Ying Huang, MS, MA, Alice S. Mims, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Christopher R. Cogle, MD, Michael M. Boyiadzis, MD, Ronan Swords, MD PhD, Robert H. Collins, MD, Jo-Anne Vergilio, M.D., Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Uma Borate, MD

1279 Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Vu H. Duong, MD, Amy S. Ruppert, PhD, Alice S. Mims, MD, Uma Borate, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William G. Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, MS, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti A. Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Christopher R. Cogle, MD, Ronan T. Swords, MD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH2, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD2, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Michael M. Boyiadzis, MD

1281 Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Maro Ohanian, DO, Tara L. Lin, MD, Ellen Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Ana Tari Ashizawa, PhD, Hagop Kantarjian, MD, Jorge E. Cortes, MD and Gail J. Roboz, MD

131 Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
Time: 1 PM
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas
Catherine Thieblemont, MD, PhD, Michael Dickinson, MBBS, Joaquin Martinez-Lopez, MD, PhD, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, Julio C. Chavez, MD, MS, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie Jose Kersten, MD, PhD, Charalambos Andreadis, MD, MSCE, Peter A. Riedell, MD, P. Joy Ho, MBBS, Jose Pérez-Simón, MD, Andy Chen, MD, PhD, Loretta Nastoupil, MD, Bastian Von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, Piers EM Patten, MB, ChB, FRCP, FRCPath, PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, MD, Pier Luigi Zinzani, MD, PhD, Ram Malladi, MD, Aiesha Zia, C Lobetti Bodoni, MD, PhD, Aisha Masood, MD, Stephen J. Schuster, MD, Nathan H. Fowler, MD and Martin H. Dreyling, MD, PhD

1373 Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I
Aung M Tun, MD, Yucai Wang, MD, Aasiya Matin, David J. Inwards, MD, Patrick B. Johnston, M.D., Ph.D., Ivana N. Micallef, MD, Luis F. Porrata, MD, Jose C. Villasboas, MD, Jonas Paludo, MD, Han W. Tun, MD, Allison C. Rosenthal, DO, James R. Cerhan, MD, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD and Stephen M. Ansell, MD, PhD

139 A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis Clinically Relevant Abstract
Time: 12 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Harinder Gill, MBBS, MD, FRCP, FRCPath, Abdulraheem Yacoub, MD, Kristen M. Pettit, MD, Terrence Bradley, MD, Aaron T. Gerds, MD, MS, Maciej Tatarczuch, BMBS, Jake Shortt, FRACP, FRCPA, PhD, Natasha Joan Curtin, MD, FRACP, FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Adam J. Mead, MBBChir, Joachim R. Göthert, MD, Steffen Koschmieder, MD, Amber Jones, MA, Jennifer Peppe, BS1, Georges Natsoulis, Ph.D., Wan-Jen Hong, MD, William S. Stevenson, MBBS, PhD, Joanne Ewing, MD, PhD, Claire N. Harrison, DM, Alessandro Vannucchi, MD, Justin Watts, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Moshe Talpaz, MD and Hugh Young Rienhoff Jr., MD

140 A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy
Time: 12:15 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Abdulraheem Yacoub, MD, Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, Minakshi S. Taparia, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD, PhD, Joseph D. Khoury, Christopher L Brooks, PhD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

142 Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
John Mascarenhas, MD, Heidi E. Kosiorek, MS, Rupali Bhave, MD, Jeanne M. Palmer, MD, Andrew T. Kuykendall, MD, Ruben A. Mesa, MD, FACP, Raajit Rampal, MD, PhD, Aaron T. Gerds, MD, MS, Abdulraheem Yacoub, MD, Kristen M. Pettit, MD, Moshe Talpaz, MD, Rami S. Komrokji, MD, Marina Kremyanskaya, MD, PhD, Agapito Gonzalez, Frank Fabris, Lonette Sandy, Kathryn Johnson, Mikaela Doughtery, Erin McGovern, BA, Juan Arango Ossa, Dylan Domenico, Noushin Farnoud, PhD, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Amy Kong, Vesna Najfeld, PhD, Carolyn Mead-Harvey, MS, Amylou C. Dueck, PhD, Lilian Varricchio, PhD and Ronald Hoffman, MD

1502 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-on Parsaclisib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib 
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Abdulraheem Yacoub, MD, Thamer Sliwa, MD, Hideto Tamura, MD, PhD, Michael Stouffs, PhD, Feng Zhou, PhD and Albert Assad, MD

240 European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication
Douglas Tremblay, MD, Andrew Srisuwananukorn, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey L. O'Connell, MD, Jamile M. Shammo, MD8, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Erin Moshier, MS, Nicole Zubizarreta and John Mascarenhas, MD

140 A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy 
Time: 12:15 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Abdulraheem Yacoub, MD, Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, Minakshi S. Taparia, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD, PhD, Joseph D. Khoury, Christopher L Brooks, PhD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

65 Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Time: 10:30 AM
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment
Jesus D Gonzalez-Lugo, MD, Suman Kambhampati, MD, Abdulraheem Yacoub, MD, William Donnellan, Prafulla Bhagat, BSc, MSc, Karen Fehn, RN, BSN, Cassady Remy, PA-C, Sakshi Jasra, MD, Mohammad Kazemi, MD, Ioannis Mantzaris, MD, MS, R. Alejandro Sica, MD, Lizamarie Bachier-Rodriguez, MD, Mendel Goldfinger, MD, Noah Kornblum, MD, Kira Gritsman, MD, PhD, Ira Braunschweig, MD, Ulrich G. Steidl, MD/PhD, Britta Will, PhD, Aditi Shastri, MD and Amit Verma, MD

1642 Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I
Tahani Atieh, DO, Shebli Atrash, MD, Meera Mohan, MD, MS, Leyla Shune, MD, Zahra Mahmoudjafari, PhD, Julie Quick, Justin Riffel, Joseph P. McGuirk, DO, Ghulam Rehman Mohyuddin, MD, Al-Ola Abdallah, MD, Nausheen Ahmed, MD, Wei Cui and Anne Wishna

1654 An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Sumit Madan, MD, Al-Ola Abdallah, MD, Andrew J. Cowan, MD, William I. Bensinger, MD, Jens Hillengass, MD, PhD, Xavier Leleu, MD, Eva Medvedova, MD, Caitlin Costello, MD, Brea Lipe, MD, Henning Schade, MD, Rajneesh Nath, MD and Liping Laura Sun, PhD

162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Time: 1:15 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid
Sagar Lonial, MD, FACP, Rakesh Popat, MBBS, FRCPath, PhD, Cyrille Hulin, Sundar Jagannath, MD, Albert Oriol, Paul G. Richardson, MD, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso and Niels W.C.J. van de Donk

1760 Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster I
Sanjeet S Dadwal, MD, Michael Shuster, MD, Gary Douglas Myers, MD, Keith Boundy, MD, Marshelle Warren, MD, Elizabeth Stoner, MD, Thuy Truong, PhD and Joshua A. Hill, MD

1791 Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Stuart Seropian, MD, Hannah Choe, MD, Mark R. Litzow, MD, Nebu V. Koshy, Patrick Stiff, MD, Camille Abboud Sr., MD, Benjamin Tomlinson, MD, Sunil Abhyankar, MD, Parameswaran Hari, Zaid S. Al-Kadhimi, MD, George L. Chen, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, James M. Foran, MD, Partow Kebriaei, MD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, MD, PhD, Michael W. Schuster, MD, Arjun Law, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Jennifer A Spross, MA, Avinash G Desai, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD, PhD

98 Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation
Rasmus T. Hoeg, MD, Anna Moroz, MD, PhD, Arpita Gandhi, MD, Lori Muffly, MD, MS, Parveen Shiraz, MD, Caspian Oliai, MD, Rohtesh S. Mehta, MD, MPH, MS, Samer A Srour, Joseph P. McGuirk, DO, Edmund K. Waller, PhD, MD, Sally Arai, MD, MS, Laura J. Johnston, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD, Wen-Kai Weng, MD, PhD, David B. Miklos, MD, PhD, Matthew J. Frank, MD, PhD, John Tamaresis, Ying Lu, PhD1, Vaibhav Agrawal, Nathaniel B Fernhoff, PhD, Gerhard Bauer, Amy Putnam, J Scott McClellan, MD, PhD, Bronwen E. Shaw, MD, PhD, Mehrdad Abedi, MD, Robert S. Negrin, MD and Everett H Meyer, MD, PhD

1847 Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Muhammad Umair Mushtaq, MD, Moazzam Shahzad, MD, Amna Y Shah, MD, Muhammad Usman Zafar, MD, Ezza Tariq, MBBS, Anam Hamid, Ayna Serwat, Iqra Anwar, MBBS, Sibgha Gull Chaudhary, MD, Nausheen Ahmed, MBBS, Sunil Abhyankar, MD, Natalie S. Callander, MD, Peiman Hematti, MD and Joseph P. McGuirk, DO

1848 Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Muhammad Umair Mushtaq, MD, Moazzam Shahzad, MD, Muhammad Usman Zafar, MD, Muhammad Arslan, MD, Ezza Tariq, MBBS, Naira Fatima, MBBS, Syeda Sadia Bokhari, MD, Javeria Shahani, Iqra Anwar, MBBS, Sibgha Gull Chaudhary, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Natalie S. Callander, MD, Peiman Hematti, MD and Joseph P. McGuirk, DO

266 An In Vivo CRISPR Screening Platform to Identify New Therapeutic Targets in AML
Time: 2:15 PM
Program: Oral and Poster Abstracts
Session: 802. Chemical Biology and Experimental Therapeutics
Shan Lin, PhD, Clement Larrue, Nastassja K. Scheidegger, Bo Kyung A. Seong, Neekesh V Dharia, MD, PhD, Caroline Wechsler, Guillaume Kugener, Amanda L Robinchaud, Amy Conway, Biniam Adane, Scott Younger, PhD, Federica Piccioni, PhD, Lynn Lee, Mark Wunderlich, MS, Jerome Tamburini and Kimberly Stegmaier, MD

1899 Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster I
Samuel David Maldonado Jr., MD, PhD, Joseph Van Galen, MD, Kyle Grose, PharmD, Michael Keng, MD and Leonid Volodin, MD

Sunday, December 12, 2021
2 Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma 
Time: 2 - 4 PM
Program: General Sessions
Session: Plenary Scientific Session
Frederick L. Locke, MD, David B. Miklos, MD, PhD, Caron Jacobson, MD, Miguel-Angel Perales, MD, Marie José Kersten, MD, PhD, Olalekan O. Oluwole, MBBS, MPH, Armin Ghobadi, MD, Aaron P. Rapoport, MD, Joseph P. McGuirk, DO, John M. Pagel, MD, PhD, Javier Muñoz, MD, MS, MBA, FACP, Umar Farooq, MD, Tom Van Meerten, MD, PhD, Patrick M. Reagan, MD, Anna Sureda, Ian W. Flinn, MD, PhD, Peter Vandenberghe, MD, PhD, Kevin Song, MD, FRCPC, Michael Dickinson, MBBS, Monique C. Minnema, MD, Peter A. Riedell, MD, Lori A. Leslie, MD, Sridhar Chaganti, MD, Yin Yang, MS, MD, Simone Filosto, PhD, Marco Schupp, MD, Christina To, MD, Paul Cheng, MD, PhD, Leo I. Gordon, MD and Jason R. Westin, MD, MS, FACP

2203 Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster II
Changya Chen, Wenbao Yu, Fatemeh Alikarami, Qi Qiu, Chia-hui Chen, Jennifer Flournoy, Peng Gao, Yasin Uzun, Li Fang, Yuxuan Hu, Qin Zhu, Kai Wang, Clara Libbrecht, Alex Felmeister, Isaiah Rozich, Yang-yang Ding, Stephen P Hunger, Hao Wu, Patrick A. Brown, MD, Erin Guest, MD, David M Barrett, Kathrin M. Bernt, MD and Kai Tan, PhD

2296 Incidence and Characteristics of Central Nervous System Involvement in Adult Acute Myeloid Leukemia Patients
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Joshua Tatarian, Heather J Male, MD, MBA, Kenneth P Byrd, DO and Tara L. Lin, MD

2316 Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Geoffrey L. Uy, MD, Vinod A. Pullarkat, MD, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung and Tara L. Lin, MD

2318 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies Clinically Relevant Abstract
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Kendra Sweet, MD, Eunice S. Wang, MD, Andrew A. Lane, MD, PhD, Haris Ali, MD, Anthony S. Stein, MD, Abdulraheem Yacoub, MD, David A. Rizzieri, MD, Sumithira Vasu, MBBS, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, James M. Foran, MD, Minakshi S. Taparia, MBBS, Todd L. Rosenblat, MD, MS, Roland B. Walter, MD, Debra Sieminski, MS, PA-C, Madhu Anant, PhD, Mrinal M. Patnaik, MBBS, Tariq I. Mughal, MD, FRCP and Marina Konopleva, MD, PhD

2316 Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Geoffrey L. Uy, MD, Vinod A. Pullarkat, MD, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung and Tara L. Lin, MD

2356 ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Jenny L. Smith, MSc, MEd, Rhonda E. Ries, MA, Yi-Cheng Wang, MS, Amanda R. Leonti, MS, Todd A. Alonzo, PhD, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Benjamin J. Huang, MD, Xiaotu Ma, PhD, Timothy I. Shaw, PhD and Soheil Meshinchi, M.D., Ph.D.

2360 Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Romy E. Van Weelderen, Kim Klein, MD, PhD, Christine J. Harrison, PhD, FRCPath, Hester A. De Groot-Kruseman, PhD, Jonas Abrahamsson, MD, PhD, Nira Arad-Cohen, MD, PhD, Emmanuelle Bart-Delabesse, PharmD, PhD, Barbara Buldini, MD, PhD, Barbara De Moerloose, Michael Dworzak, MD, PhD, Sarah Elitzur, MD, José M. Fernández Navarro, MD, Marta Fiocco, MSc, PhD, Robert B. Gerbing, MA, Bianca F. Goemans, MD, PhD, Erin Guest, MD, Shau-Yin Ha, MD, PhD, Henrik Hasle, MD, PhD, Kathy Jackson, MD, PhD, Charikleia Kelaidi, MD20*, Hélène Lapillonne, MD, PhD, Guy Leverger, MD, PhD, Franco Locatelli, MD, PhD, Takako Miyamura, MD, PhD, Sophia Polychronopoulou, MD, PhD, Mareike Rasche, MD, Jeffrey E. Rubnitz, MD, Jan Stary, Prof., MD, PhD, Daisuke Tomizawa, MD, PhD, Femke Verwer1, C. Michel Zwaan, Prof, MD, PhD and Gertjan J.L. Kaspers, Prof. MD, PhD

519 Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children’s Oncology Group
Time: 5 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis
Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Betsy A Hirsch, PhD, Beverly Lange, MD, William G. Woods, MD, Todd M. Cooper, DO, Alan S. Gamis, MD, MPH, Jessica A. Pollard, MD, Richard Aplenc, MD, PhD, Anders E. Kolb, MD and Soheil Meshinchi, M.D., Ph.D.

2424 A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Alvaro J. Alencar, MD, Lindsey E. Roeker, MD, MSCE, Marc Hoffmann, MD, Guru Subramanian Guru Murthy, MD, Vishalkumar Patel, Nora C. Ku, MD, James M. Pauff, MD, PhD, Toby A. Eyre, Wojciech Jurczak, MD, PhD and Steven Le Gouill

523 Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit 
Time: 4:30 PM
Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations
Jeremy S. Abramson, MD, Amy S. Ruppert, PhD, Sharmila Giri, MS, Ann Hudson, Eric D. Hsi, MD, Richard F. Little, MD, MPH, Steven D. Gore, MD, Anusha Vallurupalli, MD, Daniel J Landsburg, MD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD, Nancy L. Bartlett, MD and John P. Leonard, MD

2512 A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Peter A. Riedell, MD, Jamie Brower, MS, Loretta Nastoupil, MD, Miguel-Angel Perales, MD4 Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Veronika Bachanova, MD, PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Michael R. Bishop, MD and David L. Porter, MD

388 Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients 
Time: 10:15 AM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Ronald Hoffman, MD, Marina Kremyanskaya, MD, PhD, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Naveen Pemmaraju, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel Gupta, Frank Valone, MD, Sarita Khanna, PhD and Srdan Verstovsek, MD, PhD

389 Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial 
Time: 10:30 AM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Vikas Gupta, MD, FRCP, FRCPath, Abdulraheem Yacoub, MD, Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, FACP, Claire N. Harrison, DM, Giovanni Barosi, MD, Jean-Jacques Kiladjian, MD, PhD, H. Joachim Deeg, MD, Salman Fazal, MD, Lynda Foltz, MD, FRCPC, Ryan J. Mattison, MD, Carole B. Miller, MD, Vinod Parameswaran, MD, Vishwanath Gharpure, MD MRCP FACP, Christopher Hernandez, MSc, Tianhua Wang, PhD and Moshe Talpaz, MD

2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis 
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Abdulraheem Yacoub, MD, Thamer Sliwa, MD, Rosa Ayala, MD, PhD, Roberto Ferro, MD, Abdul Hai Mansoor, MD, Sue Erickson-Viitanen, PhD, Feng Zhou, PhD and Albert Assad, MD

2583 Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily Available Baseline Characteristics Clinically Relevant Abstract
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Andrew Srisuwananukorn, MD, Beth Percha, PhD, Ghaith Abu-Zeinah, MD, Joseph Scandura, MD, PhD, Spencer Krichevsky, MS, Elwood Taylor III, BS, Richard T. Silver, MD, Santiago Thibaud, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey O’Connell, MD, Jamile M. Shammo, MD, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP13, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, John Mascarenhas, MD and Douglas Tremblay, MD

538 Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
Time: 5:15 PM
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome
Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Abdulraheem Yacoub, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, James M. Foran, MD8, Ayalew Tefferi, MD, Christopher L Brooks, PhD, Guillermo Garcia-Manero, MD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

2740 SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
James E Hoffman, MD, Brea Lipe, MD, Jason Melear, MD, Michaela Liedtke, MD, Mark A. Schroeder, MD, Ruben Niesvizky, MD, Michael H. Tomasson, MD, Christopher A. Yasenchak, MD, Damian J. Green, MD, Hong Li, Yinghui Wang, MS, Phoenix Ho, MD and Al-Ola Abdallah, MD

408 Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS
Time: 10:45 AM
Program: Oral and Poster Abstracts
Session: 703. Cellular Immunotherapies: Basic and Translational II
Dries Deeren, MD, Johan A. Maertens, MD, PhD, Tara L. Lin, MD, Yves Beguin, MD, PhD, Erik Alcantar-Orozco, MD, Marie-Sophie Dheur, PhD, PharmD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, David Gilham, PhD, Anne Flament, MD and Frédéric F. Lehmann, MD

2823 Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster II
Moazzam Shahzad, MD, Muhammad Salman Faisal, MD, Ernie Shippey, Ali Hussain, MD, Clint Divine, MBA, MSM, Zahra Mahmoudjafari, PhD, Allison Appenfeller, Muhammad Umair Mushtaq, MD, Leyla Shune, MD, Joseph P. McGuirk, DO and Nausheen Ahmed, MBBS

2843 Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster II
Kitsada Wudhikarn, MD, Ana Alarcon Tomas, Jamie Brower, MS, Veronika Bachanova, MD, PhD, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Loretta Nastoupil, MD, David L. Porter, MD, Peter A. Riedell, MD and Miguel-Angel Perales, MD

2863 Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Moazzam Shahzad, MD, Sibgha Gull Chaudhary, MD, Ezza Tariq, MBBS, Naira Fatima, MBBS, Muhammad Arslan, MD, Muhammad Usman Zafar, MD, Amna Y Shah, MD, Mamoon Ahmed, Iqra Anwar, MBBS, Nausheen Ahmed, MBBS, Leyla Shune, MD, Ramesh Balusu, PhD, Peiman Hematti, MD, Joseph P. McGuirk, DO and Muhammad Umair Mushtaq, MD

2922 Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Michael T. Byrne, DO, Tony J Kurian, M2, Dilan A Patel, MD, Roni Tamari, MD, Sanghee Hong, MD, Haitham Abdelhakim, MD, Victoria Klein, Patricio Rojas, MD, Raksha Madhavan, MD, Andrew Kent, MD, PhD, Aaron C. Logan, MD, PhD, Catherine J. Lee, MD, Muhammad Husnain, MD, Benjamin M Manning, MD, PhD, Nicholas P. Tschernia, MD, Ajoy L. Dias, MD, Daniel Margalski, DO, Benjamin Goldenson, MD, PhD, Nathalie Byrne, APRN, Heidi Chen, PhD, Kseniya Petrova-Drus, MD, PhD, Salyka M. Sengsayadeth, MD, Aaron M Goodman, Dianna S. Howard, MD, William A. Wood, MD, MPH, Saar Gill, MD, PhD, Antonio M. Jimenez, MD, MSc, Jonathan A. Gutman, MD, Lohith Gowda, MD, Leland Metheny III, MD, Bhavana Bhatnagar, DO, Betty K. Hamilton, MD, Asmita Mishra, MD and Michael R. Savona, MD

 

Wednesday, December 8
GS2-07. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G.

BASIC SCIENCE FORUM – Targeting Nuclear Steroid Receptors - PR
Christy R. Hagan, PhD

Poster Session 1
P1-09-03. Omega-3 polyunsaturated fatty acid supplementation shifts the gut and breast microbiome to influence inflammation
Cook KL, Wilson AS, Soto-Pantoja DR, Kimler BF, Umar S, Fabian CJ. 

P1-10-04.  AGR2, an estrogen response gene associated with tamoxifen resistance, is modulated by acolbifene in premenopausal women at high risk for development of breast cancer
Fabian CJ, Phillips TA, Kimler BF

Poster Session 2
P2-01-05.  Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease
Sharma P, Stecklein SR, Kimler BF, Yoder R, Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab J, Home T, Hyter S, Isakova K, Pathak HB, Godwin AK.

P2-10-02.  Random periareolar fine-needle aspiration (RPFNA) cell number, prior precancerous breast disease and subsequent uptake of a prevention intervention predict short-term breast cancer risk
Hensing WL, Fabian CJ, Zalles CM, Sharma P, Kreutzjans AL, Powers KR, Chollet-Hilton L, Kimler BF.

P2-11-17.  Feasibility of microbiome analysis from random periareolar fine needle aspiration in premenopausal women at increased risk for breast cancer
Nye LE, Klemp JR, Powers KR, O'Dea AP, Kreutzjans AL, Metheny T, Phillips TA, Carlson SE, Kimler BF, Fabian CJ.

P2-11-21.  Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model
Hughes E, Bernhisel R, Pederson H, Probst B, Simmons T, Wagner S, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Gordon OK, Klemp J, Mukherjee S, Offit K, Olopade F, Vijai J, Weitzel J, Whitworth P, Yehia L, Kurian A, Robson M, Slavin TP, Gutin A, Lanchbury JS.

P2-13-34.  A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
Rooney A, Sharma P, O'Dea AP, Nye L, Elia M, He J, Fabian C, Khan Q.

Thursday, December 9

Spotlight Poster Discussion 8 - HER2 Positive Breast Cancer 
Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes
Priyanka Sharma, MD

Poster Session 3
P3-17-03.  Raising the level of cancer care around the world: The feasibility and perceived benefit of a virtual breast tumor board
Dempsey N, Chiec L, Lodder M, Shonkwiler E, Haines K, Mahtani R, Gradishar W, Buchholz T, O'Dea A, Wolmark N, Hurvitz S, O'Shaughnessy J, Jochelson M, Butler R, Mamounas E, Vicini F, Pegram M, Shah C, King T, O'Regan R, Morrow M, Jahanzeb M. Lynn

Poster Session 4 
P4-01-16.  Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR
Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L.

P4-04-07.  Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang X-Y, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR.

P4-10-03.  Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer
Bivona C, Li K, Sharma P, He J, Martin G, Godwin AK, Rooney A, Williamson S, Doolittle G, Sun W, Kimler BF, O'Dea AP, Nye LE, McGuirk JP, Pessetto Z, Haney LH, Balmaceda N, Mitchell L, Finke K, Nelson M, Pal Mudaranthakam D, Streeter N, Lafaver S, Heldstab J, Khan QJ.

Spotlight Poster Discussion
PD9-06.  Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial
Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner FL, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A.

Friday, December 10

GS4-02. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Kyalwazi B, Yau C, Olopade O, A. Chien J, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van ‘t Veer L, Berry D, Esserman L.

Poster Session 5
P5-01-03.  Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy
Behbod F, Hong Y, Limback D, Elsarraj HS, Rastogi A, Harper H, Ricci M, Kaufman C, Redick M, Wedlock E, Zhang J, May L, Cusick T, Inciardi M, Gatewood J, Winblad O, Aripoli A, Huppe A, Balanoff C, Wagner J, Amin A, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Hilsenbeck SG, Futreal A, Thompson A, Hwang ES, Fan F

P5-04-05.  Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression
Vargheese AM, Cloud AS, Gunewardena S, Shimak RM, Ganeshkumar S, Kumaraswamy E, Jensen RA, Chennathukuzhi VM. 

Case-Based Panel Session: Understanding and Managing Chronic Effects of the Cancer Experience.
Available via pre-broadcast on June 4, 2021
Panel chair: Sean Robinson Smith
Panelists: Judith Paice, Candace Henley, Jamie S. Myers.

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract 7033: Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.
Muhammad Umair Mushtaq, Mary Luder, Moazzam Shahzad, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Sibgha Gull Chaudhary, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K Singh, Sunil H. Abhyankar, Siddhartha Ganguly, Joseph McGuirk.

Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract 10580:  Point of care genetic testing in a breast cancer survivorship clinic.
Lori Ranallo, Lauren Elizabeth Nye, Mary Williams, Carol J. Fabian, Anne O'Dea, Jennifer R. Klemp.

Abstract 10502:  Ancestrally unbiased polygenic breast cancer (BC) risk assessment.
Elisha Hughes, Placede Tiemeny, Shannon Gallagher, Stephanie Meek, Charis Eng, Monique Gary, Ora Gordon, Jennifer R. Klemp, Olufunmilayo I. Olopade, Holly Jane Pederson, Jeffrey N. Weitzel, Pat W. Whitworth, Lamis Yehia, Susanne Wagner, Thomas Paul Slavin, Alexander Gutin, Jerry Lanchbury

Session: Health Services Research and Quality Improvement
Abstract 6552:  Effect of income on patient decision-making in localized prostate cancer.
Xinglei Shen, Ying Cao, Aaron J. Katz, Deborah Usinger, Sarah Walden, Ronald C. Chen

Abstract 6578:  Associations between patient knowledge of others' experiences and treatment choice in men with localized prostate cancer.
Aaron J. Katz, Ying Cao, Xinglei Shen, Deborah Usinger, Sarah Walden, Ronald C. Chen

Abstract 6556:  In-hospital outcomes of CAR T-cell therapy in United States in 2018: A nationwide analysis.
Manoj P. Rai, Prabhjot Singh Bedi, Anup Kasi, Kathan Mehta

Abstract 6519:  Racial and ethnic representation trends in United States oncology training programs.
Conner Lombardi, Jacob Lang, Rochell Issa, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

Abstract 6509:  Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.
Kathryn Finch Mileham, Suanna Steeby Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel Mesenhowski, Alexander I. Spira, Eric J. Clayton, David Michael Waterhouse, Sue Moore, Abdul-Rahman Jazieh, Ronald C. Chen, Melinda Kaltenbaugh, Jen Hanley Williams, Richard L. Schilsky, Liz Garrett-Mayer

Abstract 6500:  Racial and ethnic disparities among patients with breast cancer and COVID-19.
Gayathri Nagaraj, Melissa Kate Accordino, Benjamin French, Nicole M. Kuderer, Gary H. Lyman, Daniel G. Stover, Victoria Susana Blinder, Andrew Lachlan Schmidt, Rebecca Arielle Shatsky, Punita Grover, Matthew Puc, Clara Hwang, Elizabeth Marie Wulff-Burchfield, Mark Andrew Lewis, Alvaro G. Menendez, Mehmet Asim Bilen, Jeremy Lyle Warner, Maryam B. Lustberg, Dimpy P Shah

Session: Developmental Therapeutics—Immunotherapy
Abstract TPS2678:  Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.
Takefumi Komiya, Jun Zhang, Prakash C. Neupane, Kathan Mehta, Chao Hui Huang

Abstract 2510:  Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
Stephen K. Williamson, F. Stephen Hodi, Melissa Lynne Johnson, Minal A. Barve, Dejan Juric, Joaquina Celebre Baranda, Reva Elaine Schneider, Todd Michael Bauer, Tun Tun Lin, Rui Wang, Amele Amrate, Helene Guillemin-Paveau, Ryan J. Sullivan

Abstract 2534:  PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.
Matthew H. Carabasi, Meredith McKean, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Russell Kent Pachynski, Rahul Atul Parikh, Jingsong Zhang, Thomas J. Fountaine, Jamie Rosen, Pam Hufner, Whitney Gladney, Karen Chagin

Abstract 2536:  Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.
Antonio Jimeno, Joaquina Celebre Baranda, Monica M. Mita, Michael S. Gordon, Matthew H. Taylor, Wade Thomas Iams, Filip Janku, Ursula A. Matulonis, Howard Bernstein, Scott Loughhead, Martin Kornacker, Ricardo F. Zwirtes, Oliver Rosen, Cathy Eng

Abstract TPS2661: Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
Adam Jacob Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra P. D'Angelo, Brian H. Ladle, Jonathan Christopher Noujaim, Kai He, David A. Liebner, Adrian G. Sacher, John B. A. G. Haanen, Jeffrey Yachnin,Chao H. Huang, Brian Andrew Van Tine, Aisha N. Hasan, Thomas H. Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo

Session: Breast Cancer—Metastatic
Abstract 1076:  Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, Lauren Elizabeth Nye, Ingrid A. Mayer, Gregory James Crane, Manana Elia, Rachel Yoder, Joshua M Staley, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Stephen K. Williamson, Milind Phadnis, Gregory A Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin

Abstract 1077:  Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
Joyce O'Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Hope S. Rugo

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract TPS7058:  A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.
Abdulraheem Yacoub, Susan Erickson-Viitanen, Feng Zhou, Albert Assad

Abstract 7026:  Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
Vinod Pullarkat, Mark J. Levis, Gabriel N. Mannis, Stephen Anthony Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald Cheung, Harry Paul Erba

Session: Gastrointestinal Cancer—Colorectal and Anal
Abstract 3357:  Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.
Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed

Abstract 3563:  Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
Emil Lou, Yasmine Baca, Joanne Xiu, Andrew Nelson, Subbaya Subramanian, Mohamed E. Salem, Muhammad Shaalan Beg, Elisa Fontana, Maria Diab, Philip Agop Philip, Richard M. Goldberg, Ritu Pandey, Tobias Arkenau, Weijing Sun, Heinz-Josef Lenz, Anthony Frank Shields, Wafik S. El-Deiry, Wolfgang Michael Korn

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract 4091:  Relationship between Helicobacter pylori and development of hepatocellular carcinoma: A systematic review and meta-analysis.
Samragnyi Madala, Kira MacDougall, Balarama Krishna Surapaneni, Robin Park, Anup Kasi, Mohit Girotra

Abstract 4086:  Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh'd Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David H. Gallinson, Adrian Gerard Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Christine Francis Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel

Abstract 4085: Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.
Alessio Cortellini, Thomas Urban Marron, Pallavi Shruti Mishra-Kalyani, Yutao Gong, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Uqba Khan, Ahmed Omar Kaseb, Yi-Hsiang Huang, Celina Ang, Julie A. Schneider, Anjana Pillai, Lorenza Rimassa, Richard Pazdur, Marc Robert Theoret, Steven Lemery, Lorraine Cheryl Pelosof, David James Pinato

Session: Sarcoma
Abstract TPS11578:  A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Jay Oza, Shing Mirn Lee, Mia C. Weiss, Brittany L Siontis, Benjamin C. Powers, Warren Allen Chow, Wendy Magana, Tahir Sheikh, Richard Piekarz, Gary K. Schwartz, Matthew Ingham

Abstract 11523:  Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Michael J Wagner, Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah, Ali Raza Khaki, Lisa May Ling Tachiki, Elizabeth Trice Loggers, Chris Labaki, Rana R. McKay, Elizabeth A. Griffiths, Katherine Anne Thornton, Anup Kasi, Clara Hwang, James Lin Chen, Thorvardur Ragnar Halfdanarson, Daniel Y. Reuben, Cathleen Park, Elizabeth J. Davis

Session: Professional Development and Education Advances
Abstract 11020:  Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.
Raheel Sufian Siddiqui, Moazzam Shahzad, Mahrukh Majeed, Ali Hussain, Faryal Murtaza, Farhan Khalid, Ayesha Habib, Zobia Aijaz, Syeda Sadia Bukhari, Iqra Anwar, Sehar Altaf, Faiz Anwer, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Siddhartha Ganguly, Sunil H. Abhyankar, Joseph McGuirk, Faisal Khosa, Muhammad Umair Mushtaq

Abstract 11043:  Representation trends in radiation oncology training programs in the United States.
Emilie Garcia, Jacob Lang, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract TPS7570:  A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
Joseph McGuirk, Carlos R. Bachier, Michael Russell Bishop, P. Joy Ho, Hemant S. Murthy, Michael J. Dickinson, Joseph E. Maakaron, Charalambos Andreadis, Armin Ghobadi, Edmund K. Waller, Mark Daniel Benton, Susanna Suh, Huansheng Xu, Ewelina Morawa, Farrukh Tauseef Awan, Paul Shaughnessy, Constantine Si Lun Tam, Nicolaus Kroeger, Richard T. Maziarz

Session: Genitourinary Cancer—Kidney and Bladder
Abstract 4568:  Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.
Dharmesh Gopalakrishnan, Katharine Collier, Joseph J Park, Jacob P Zaemes, Elaine Tat Lam, Sabah Alaklabi, Ellen Jaeger, Rahul Atul Parikh, Pedro C. Barata, Eric Kauffman, Michael B. Atkins, Ajjai Shivaram Alva, Yuanquan Yang, Saby George

Abstract 4507:  A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
Authors:  Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, Rahul Atul Parikh, Benjamin A. Teply, Robert Dreicer, Hamid Emamekhoo, M. Dror Michaelson, Christopher J. Hoimes, Tian Zhang, Sandy Srinivas, William Y. Kim, Glenn Liu, Paul Henry Frankel, Yuijie Cui, Primo "Lucky" N. Lara

Abstract TPS4593:  A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
Authors:  Rana R. McKay, Heather Jacene, Pamela J. Atherton, Gabriela Perez Burbano, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler J. Zemla, Ronald C. Chen, Atish Dipankar Choudhury, Joshua Michael Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Himisha Beltran, Daniel J. George, Michael J. Morris, Toni K. Choueiri

Session: Gynecologic Cancer
Abstract 5576:  Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
Filip Janku, Erika P. Hamilton, Cara Amanda Mathews, Christina Chu, Jennifer Robinson Diamond, John L. Hays, Rebecca Christian Arend, Massimo Cristofanilli, Andrea Jewell, William Reichmann, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, Debra L. Richardson

Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract 5071:  The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
Andrew J. Armstrong, Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Zelig Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgioti, Nader N. El-Chaar, Arnulf Stenzl
  
Session: Symptoms and Survivorship
Abstract 12035:  Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.
Elizabeth Trice Loggers,Elizabeth Marie Wulff-Burchfield, Ishwaria Mohan Subbiah, Ali Raza Khaki, Pamela Egan, Dimitrios Farmakiotis, Hardeep Phull, Elizabeth Nakasone, Chris Labaki, Peter Paul Yu, Monika Joshi, Elizabeth A. Griffiths, Trisha Michel Wise-Draper, Chinmay Jani, Astha Thakkar, Matthew Puc, Clara Hwang, Blanche H. Mavromatis, Dimpy P Shah, Jeremy Lyle Warner

Session: Melanoma/Skin Cancers
Abstract 9515:  Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa Lynne Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, Alexander I. Spira, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha Nicholle Sims, Glenn Kroog

Session: Biomarker-Driven Approaches for the Treatment of Gastrointestinal Cancers
Abstract 4010:  FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Daniel V.T. Catenacci, Yoon-Koo Kang, Anwaar Saeed, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee, In-Ho Kim, Sang Cheul Oh, Jin Li, Haci M. Turk, Alexandra Carolina Teixeira, Christophe Borg, Erika Hitre, Anghel Adrian Udrea, Giovanni Gerardo Cardellino, Raquel Guardeno, Siddhartha Mitra, Yingsi Yang, Peter C. Enzinger, Zev A. Wainberg

Session: Pediatric Oncology
Abstract 10051:  Standardization of fertility preservation discussion amongst pediatric oncology and bone marrow transplant patients.
Chandni Dargan, Sarah Mc Dermott, Shelby Chesbro, Joy M. Fulbright

Session: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract e16194:  Efficacy of immunotherapy in hepatocholangiocarcinoma (HCC-CC): Proof of concept.
Osama Diab, Maloree Khan, Saqib Abbasi, Anwaar Saeed, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Raed Moh'd Taiseer Al-Rajabi

Abstract e16273:  Early detection of pancreatic cancers by novel nanobiosensor-based protease biomarkers using hierarchical decision structure.
Anup Kasi, Weijing Sun, Sumia Ehsan, Jose Covarrubias, Kayla Eschliman, Raul Neri, Deepesh Agarwal, Obdulia Covarrubias Zambrano, Stefan H Bossmann, Bala Natarajan

Session: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Abstract e15613:  A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Anup Kasi, Pramod Gaudel, Joseph Bennett, Raed Moh'd Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Weijing Sun, Charles B. Porter

Session: Publication Only: Health Services Research and Quality Improvement
Abstract e18578:  Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.
Robin Park, Elizabeth Marie Wulff-Burchfield,Kathan Mehta,Weijing Sun,Anup Kasi

Abstract e18562:  Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART.
Nausheen Ahmed, Ernie Shippey, Crissy Kus, Allison Appenfeller, Marc Steven Hoffmann, Aung M. Tun, Siddhartha Ganguly,Leyla Shune, Clint Devine, Rajat Bansal, Sunil H. Abhyankar, Muhammad Umair Mushtaq, Joseph McGuirk

Abstract e18611:  Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.
Sibgha Gull Chaudhary, Muhammad Usman Zafar, Maha Awaiz Hassan, Moazzam Shahzad, Ali Hussain, Fatima Ali, Yumna Riaz, Fatima Khalid, Sharad Khurana, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh, Faiz Anwer, Sunil H. Abhyankar,Joseph McGuirk, Muhammad Umair Mushtaq

Session: Publication Only: Care Delivery and Regulatory Policy
Abstract e13615:  Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.
Nausheen Ahmed, Sarah Fitzmaurice, Cherie Morey, Tania Torres, Darla Beckman, Siddhartha Ganguly, Rajat Bansal, Liza Rodriguez, Haitham Abdelhakim, Anurag K Singh,Sunil H. Abhyankar, Leyla Shune, Robert Kribs, Clint Devine, Jennifer Hanses, Muhammad Umair Mushtaq, Joseph McGuirk

Session: Publication Only: Lung Cancer—Non-Small Cell Metastatic
Abstract e21024:  Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
Justin Chau, Meeta Yadav, Ben Liu, Muhammad Furqan, Qun Dai, Shailesh Shahi, Arnav Gupta, Keri Nace Mercer, Evan Eastman, Taher Abu Hejleh, Carlos Hou Fai Chan, George J. Weiner, Catherine Cherwin, Sonny T.M. Lee, Cuncong Zhong, Ashutosh Mangalam, Jun Zhang
  
Session: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract e17012:  Nationwide trends in in-patient chemotherapy hospitalizations, cost, and mortality for patients with testicular carcinoma.
Saqib Abbasi, Elizabeth Marie Wulff-Burchfield,Rahul Atul Parikh

Abstract e17020:  A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.
Rana R. McKay, Wanling Xie, Archana Ajmera, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Atish Dipankar Choudhury, David Johnson Einstein, Elisabeth I. Heath, Rahul Atul Parikh, Charles Kunos, S. Percy Ivy, Geoffrey Shapiro, Razelle Kurzrock

Session: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract e19537:  Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
Ulrich Jäger, Nina Worel, Joseph McGuirk, Peter A. Riedell, Isabelle Fleury, Peter Borchmann, Yan Du, Ahmed M. Abdelhady, Xia Han, Marcela Martinez-Prieto, Edmund K. Waller

Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract e19014:  Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.
Syed Ather Hussain, Atif N khan, VENKATA S THAMMINENI, Muhammad Nauman Riaz, Moazzam Shahzad, Priyanjali Pulipati, Fatima Khalid, Zahoor Ahmed, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Muhammad Umair Mushtaq

Abstract e19002:  MRD assessment using NGS in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation: Meta-analysis.
Osama Mosalem, Mahmoud Abdelsamia, Haitham Abdelhakim

Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract e19035:  Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.
Razwana Khanam, Moazzam Shahzad, Pranali Santhoshini Pachika, Zahoor Ahmed, Fatima Ali, Adeel Masood, Zunairah Shah, Asmi Chattaraj, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Sunil H. Abhyankar,Joseph P McGuirk, Muhammad Umair Mushtaq

Abstract e19025: Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.
Abdul Basit, Moazzam Shahzad, Sibgha Gull Chaudhary, Fatima Khalid, Nausheen Ahmed, Sharad Khurana, Siddhartha Ganguly,Sunil H. Abhyankar, Joseph McGuirk, Muhammad Umair Mushtaq

Abstract e19012: Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.
Moazzam Shahzad, Iqra Anwar, Raheel Sufian Siddiqui, Tehniat Faraz Ahmed, Mahrukh Majeed, Maha Awaiz Hassan, Zahoor Ahmed, Karun Neupane, Tayyaba Ali, Muhammad Salman Faisal, Masooma Naseem, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh,Sunil H. Abhyankar,Joseph McGuirk, Faiz Anwer, Muhammad Umair Mushtaq

April 9
SY02.OD - Options and Opportunities for Treating Metastasis
On Demand
Friday, April 9, 2021: 12:05 AM - 11:59 PM
Chairperson: Danny R. Welch (CB)
Using the hallmarks of metastasis to develop antimetastatic treatments

April 10
PO.CL06.03 - Immune Checkpoints
485 - Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study.
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Petros Fessas, Muntaha Naeem, Thomas U. Marron, David Szafron, Elad Sharon, Anwaar Saeed (D3ET), Tomi Jun, Sirish Dharmapuri, Abdul R. Naqash, Thoetchai Peeraphatdit, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, ChiehJu Lee, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, David J. Pinato.

PO.CL06.04 - Immune Mechanisms Invoked by Therapies
505 - Oral azacitidine modulates the immune microenvironment in acute myeloid leukemia (AML) patients in remission: A subanalysis from the QUAZAR AML-001 Trial
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Daniel L. Menezes, Wendy L. See, Alberto Risueno, Jianglin Ma, Ignazia La Torre, Barry Skikne, CL Beach, Keshava Kumar, Anjan Thakurta.

PO.CL06.05 - Immune Monitoring / Clinical Correlates
509 - Conversion of cellular kinetic data for chimeric antigen receptor T-cell therapy (CAR-T) into interpretable units
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Anwesha Chaudhury, Andrew Stein, Stephan Grupp, John Levine, Michael Pulsipher, G Doug Myers (D3ET), Edward Waldron, Xu Zhu, Fraser McBlane, Rakesh Awasthi, Edmund K. Waller. 

510 - Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL)
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Irina Gershgorin, Edward R. Waldron, Stephan A. Grupp, John E. Levine, Michael A. Pulsipher, Stella M. Davies, G. Doug Myers (D3ET), Margit Jeschke, Boris Engels, Chris Del Corral, Andre Baruchel. 

PO.CT01 - Phase I Clinical Trials
CT131 - A Phase I safety and tolerance study of FN-1501, a novel FLT3 inhibitor, in patients with advanced solid tumors and acute myeloid leukemia
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Gary Edward Richardson, Stephen K. Williamson (D3ET), Misako Nagasaka, Viviana Bozon, Maria Margarita Corvez, Chao Li, Wei Li, Jiao Wei, Ai-Min Hui.

PO.CT02 - Phase II Clinical Trials
CT162 - Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Abdulraheem Yacoub (D3ET), Eunice S. Wang, Raajit K. Rampal, Uma Borate, Marina Kremyanskaya, Haris Ali, Gabriela S. Hobbs, Casey O'Connell, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Timothy C. Burn, Naval G. Daver.

CT164 - Pharmacological ascorbate enhances platinum-based chemotherapy responses in metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Muhammad Furqan, Taher Abu-Hejleh, Kellie L. Bodeker, Laura M. S. Pietrok, Stacey M. Hartwig, Mikaela M. Tremblay, Micaela G. Fosdick, Jon Houtman, Steven Varga, Casey F. Pulliam, Michael Petronek, Melissa A. Fath, Sarah L. Mott, Aaron D. Bossler, Andrew M. Bellizzi, Jun Zhang (D3ET), Hariharasudan Mani, Varun Monga, Brian J. Smith, Joseph Cullen, Brett A. Wagner, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen.

PO.CT08.01 - Phase I Clinical Trials in Progress
CT219 - Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Adam J. Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra D’Angelo, Brian H. Ladle, Jonathan Noujaim, Kai He, David Liebner, Adrian G. Sacher, John B.A.G. Haanen, Jeffrey Yachnin, Chao Huang (D3ET), Brian A. Van Tine, Aisha Hasan, Thomas Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo.

PO.CT08.03 - Phase III Clinical Trials in Progress
CT252 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Abdulraheem Yacoub (D3ET), Sue Erickson-Viitanen, Feng Zhou, Albert Assad.

CT253 - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Abdulraheem Yacoub (D3ET), Michael Stouffs, Feng Zhou, Albert Assad.

PO.EP01.02 - Biomarkers of Prognosis
774 - Methylation-derived biologic age, telomere length, and lung cancer mortality in heavy smokers from CARET
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Laurie Grieshober, Stefan Graw, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Chu Chen, Devin C. Koestler (CB), Carmen J. Marsit, Jennifer A. Doherty.

PO.EP01.11 - Infection and Immune Factors
LB086 - Methylation-derived neutrophil-to-lymphocyte ratio and lung cancer risk and survival
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Naisi Zhao, Mengyuan Ruan, Devin C. Koestler (CB), Jiayun Lu, Carmen Marsit, Karl Kelsey, Elizabeth Platz, Dominique S. Michaud.

PO.ET03.05 - Reversal of Drug Resistance
1413 - Targeting the RNA-binding protein HuR to overcome chemoresistance in triple-negative breast cancer
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Lanjing Wei, Qi Zhang, Cuncong Zhong, Jeffrey Aubé, Danny R. Welch (CB), Xiaoqing Wu (D3ET), Liang Xu (D3ET).

PO.IM02.02 - Combination Immunotherapies
1560 - Targeting RNA-binding protein HuR to improve anti-PD-1 immunotherapy response in breast cancer
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Qi Zhang, Xiaoqing Wu (D3ET), Lan Lan, Lanjing Wei, Liang Xu (D3ET).

PO.MCB08.04     
2467 - Adiponectin receptor agonism induces a metabolic switch in pancreatic cancer cells from oxidative phosphorylation to glycolysis
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Sharon J. Manley, Jarrid Jack, Joseph Ambrose, Appolinaire A. Olou, Michael N. VanSaun (CB). 

PO.PR01.01 - Preclinical Prevention, Early Detection, and Interception
2567 - Duavee® improves metabolic health without increasing cancer risk: findings from a preclinical model of obesity and postmenopausal breast cancer
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Karen A. Corleto, Tara N. Mahmood, Danilo Landrock, Stephen D. Hursting, Carol J. Fabian (CPC), Bruce F. Kimler (CPC), Erin D. Giles.

PO.TB04.02 - Invasion and Metastasis 2
2899 - On the cutting edge of the leading edge: investigating the role of DCLK1 in invadopodia
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Levi K. Arnold, Michael Barry, Prabhu Ramamoorthy (CB), Brendan Otteman, Shrikant Anant (CB).

PO.TB06.01 - Chemokines in the Tumor Microenvironment
2687 - Secretory autophagy offers a novel therapeutic target for head and neck squamous cell carcinoma
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Brendan M. Ottemann, Lauryn Werner, Sufi Thomas (CB)

PO.TB06.06 - Microbiome
2911 - Intersection of aging, the microbiome and inflammation in a mouse model of bladder cancer
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Benjamin L. Woolbright (D3ET), Erika Abbott, Ganeshkumar Rajendran, Cuncong Zhong, Hao Xuan, Shahid Umar (CPC),  John Arthur Taylor III (D3ET).

PO.TB06.07 - Tumor/Stromal Interactions
3168 - Pancreatic cancer lipid theft is mediated by MAP Kinase signaling in adipocytes
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Joseph Ambrose, Austin E. Eades, McKinnon Walsh, Michael N. VanSaun (CB).

3170 - Targeting tumor-associated astrocyte dependence in glioblastoma treatment
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Joseph S. Domino, Anthony Alvarado, Levi Arnold, Sumedha Gunewardena, David Akhavan (D3ET), Sufi M. Thomas (CB)

PO.TB06.10 - Inflammation and the Tumor Microenvironment
2824 - SHP2-PDHA metabolic axis is critical for adipocyte function by mitigating ER stress-induced adipocytes dysfunction: Implication for obesity-driven pancreatic ductal adenocarcinoma progression.
Saturday, April 10, 2021: 8:30 AM - 11:59 PM
Appolinaire A. Olou, Jarrid Jack, Sharon Manley, Joseph Ambrose, McKinnon Walsh, Austin Eades, Michael N. VanSaun (CB).

MS.MCB01.01 - Cell Growth Signaling Pathways
Saturday, April 10, 2021: 4:00 PM - 6:00 PM
Channel 06
Chairperson: Sufi M. Thomas (CB).

April 12
SS03 - NextGen Stars Spotlight Session: Immunology and Targeted Therapy
Progesterone-mediated immune evasion in breast cancer
Monday, April 12, 2021: 2:51 PM - 3:06 PM
Christy R. Hagan (CB), Lauryn Werner, Emma Helm, Margaret Axelrod, Justin Balko, Zachary Hartman, Kent Hunter, Howard Yang, Prabhakar Chalise (CPC), Mary Markiewicz (CB).

April 15
SY02.DISC - Panel— Options and Opportunities for Treating Metastasis
Wednesday, April 15, 2021: 11:30 AM - 12:00 PM
Chairperson: Danny R. Welch (CB)